somnolence B-NEG

-DOCSTART- O

blood B-NEG
wind I-NEG
of O
female O

-DOCSTART- O

Different O
poisoning B-NEG
, O

-DOCSTART- O

pain B-NEG
in O
ear O

-DOCSTART- O

Septic B-NEG
Shock I-NEG

-DOCSTART- O

frost B-NEG
bite I-NEG
; O
chilblain B-NEG
; O
frostbite B-NEG

-DOCSTART- O

disperse O
accumulation B-NEU
and O
kill O
worm B-NEG

-DOCSTART- O

Huperzine O
B O
has O
been O
found O
to O
be O
an O
inhibitor O
of O
the O
enzyme O
acetylcholinesterase O
. O

This O
is O
the O
same O
mechanism O
of O
action O
of O
pharmaceutical O
drugs O
such O
as O
galantamine O
and O
donepezil O
used O
to O
treat O
Alzheimer's B-NEG
disease I-NEG
. O

-DOCSTART- O

venomous O
snake-bite B-NEG

-DOCSTART- O

( O
1 O
) O
cold-type O
hernia B-NEG
; O
periumbilical O
colic B-NEG
due O
to O
invasion O
of O
cold B-NEG
( O
2 O
) O
testalgia B-NEG
due O
to O
pathogenic O
cold B-NEG

-DOCSTART- O

nocturnal B-NEU
emission I-NEU
; O

emission B-NEU
; O

spermatorrhea B-NEG
; O

seminal B-NEU
emission I-NEU

-DOCSTART- O

convulsion B-NEG
; O

epilepsy B-NEG

-DOCSTART- O

Rivanicline O
is O
a O
( O
E)-metanicotine O
hemigalactarate O
. O
It O
effectively O
inhibits O
TNF- O
and O
LPB-induced O
IL-8 B-DNP
production O
in O
different O
cell O
types O
. O

-DOCSTART- O

reinforce O
the O
spleen B-DNP

-DOCSTART- O

affection B-NEG
due O
to O
wind-heat B-NEG
; O
common O
cold B-NEG
of O
the O
wind-heat B-NEG
type O
; O
flu B-NEG
caused O
by O
wind B-NEG
and O
heat B-NEU

-DOCSTART- O

Yokukansan O
( O
YKS O
) O
is O
a O
traditional O
Japanese O
medicine O
consisting O
of O
seven O
medicinal O
herbs O
that O
is O
used O
for O
the O
treatment O
of O
neurosis B-NEG
, O
insomnia B-NEG
, O
and O
the O
behavioral/psychological O
symptoms O
of O
dementia B-NEG
. O

This O
study O
examined O
the O
effects O
of O
YKS O
on O
morphine O
tolerance O
and O
physical O
dependence O
in O
mice O
. O

Daily O
oral O
administration O
of O
YKS O
( O
0.5 O
or O
1 O
g/kg O
) O
for O
3 O
weeks O
significantly O
attenuated O
morphine O
tolerance O
and O
naloxone-precipitated O
morphine O
withdrawal O
signs O
( O
jumps O
and O
body O
weight O
loss O
) O
without O
affecting O
the O
analgesic O
effect O
of O
morphine O
. O

The O
inhibitory O
effect O
of O
YKS O
on O
withdrawal O
jumps O
in O
morphine-dependent O
mice O
was O
blocked O
by O
a O
single O
pretreatment O
with O
an O
a(2)-adrenoceptor B-DNP
antagonist O
, O
yohimbine O
, O
but O
not O
by O
an O
a(1)-adrenoceptor B-DNP
antagonist O
, O
prazosin O
. O

A O
similar O
inhibitory O
effect O
on O
withdrawal O
jumps O
was O
observed O
by O
repeated O
administration O
of O
yohimbine O
. O

The O
membrane O
expression O
of O
a(2A)-adrenoceptors B-DNP
in O
the O
pons/medulla O
was O
decreased O
in O
morphine O
withdrawn O
animals O
; O
this O
reduction O
was O
prevented O
by O
repeated O
administration O
of O
YKS O
or O
yohimbine O
. O

Competitive O
radioligand O
and O
[(35)S]guanosine-5'-O-(3-thiotriphosphate O
) O
binding O
assays O
revealed O
that O
YKS O
and O
its O
constituent O
herbs O
, O
Glycyrrhiza O
( O
GR O
) O
and O
Uncaria O
hook O
( O
UH O
) O
, O
had O
specific O
binding O
affinity O
for O
and O
antagonist O
activity O
against O
the O
a(2A)-adrenoceptor B-DNP
. O

Certain O
chemical O
constituents O
, O
including O
GR O
- O
derived O
glycyrrhizin O
and O
its O
metabolite O
, O
18b-glycyrrhetinic O
acid O
, O
and O
UH-derived O
geissoschizine O
methyl O
ether O
( O
GME O
) O
, O
shared O
such O
activities O
. O

Repeated O
administration O
of O
GR O
, O
UH O
, O
glycyrrhizin O
or O
GME O
significantly O
inhibited O
morphine O
withdrawal O
signs O
. O

These O
results O
suggest O
that O
YKS O
and O
its O
active O
constituents O
inhibit O
morphine O
tolerance O
and O
physical O
dependence O
, O
and O
that O
the O
latter O
is O
due O
at O
least O
in O
part O
to O
the O
prevention O
of O
the O
decreased O
membrane O
expression O
of O
the O
a(2A)-adrenoceptor B-DNP
in O
the O
brainstem O
by O
its O
prolonged O
blockade O
. O

-DOCSTART- O

To O
astringe O
intestines B-DNP
and O
check O
diarrhea B-NEG
, O
resolve O
toxin B-NEG
, O
relieve O
itch B-NEG
. O

-DOCSTART- O

For O
the O
treatment O
of O
bacterial B-NEG
infections I-NEG
. O

-DOCSTART- O

Counteracting O
the O
arrhythmias B-NEG
induced O
pituitrin O
in O
rabbits. O
. O

-DOCSTART- O

Its O
leaf O
infusion O
from O
NaCl O
solution O
inhibits O
the O
growth O
of O
Bacillus B-NEG
coli I-NEG
. O

-DOCSTART- O

Carcinoma B-NEG
of I-NEG
mammary I-NEG
glands I-NEG
, O
nasopharyngeal B-NEG
carcinoma I-NEG
, O
carcinoma B-NEG
of I-NEG
salivary I-NEG
gland I-NEG
, O
scrofula B-NEG
, O
swelling B-NEG
of I-NEG
skin I-NEG
, O
pain B-NEG
wind I-NEG
. O

-DOCSTART- O

Penbutolol O
is O
indicated O
in O
the O
treatment O
of O
mild O
to O
moderate O
arterial B-NEG
hypertension I-NEG
. O

It O
may O
be O
used O
alone O
or O
in O
combination O
with O
other O
antihypertensive O
agents O
, O
especially O
thiazide-type O
diuretics O
. O

Penbutolol O
is O
contraindicated O
in O
patients O
with O
cardiogenic B-NEG
shock I-NEG
, O
sinus B-NEG
bradycardia I-NEG
, O
second B-NEG
and I-NEG
third I-NEG
degree I-NEG
atrioventricular I-NEG
conduction I-NEG
block I-NEG
, O
bronchial B-NEG
asthma I-NEG
, O
and O
those O
with O
known O
hypersensitivity B-NEG
. O

-DOCSTART- O

critical B-NEG
symptom I-NEG
complex I-NEG
with O
complicated O
, O
changable O
and O
serious O
conditions O
; O

disease B-NEG
due O
to O
the O
poisonous B-NEG

-DOCSTART- O

Tetracycline O
passively O
diffuses O
through O
porin B-DNP
channels I-DNP
in O
the O
bacterial O
membrane O
and O
reversibly O
binds O
to O
the O
30S O
ribosomal O
subunit O
, O
preventing O
binding O
of O
tRNA O
to O
the O
mRNA-ribosome O
complex O
, O
and O
thus O
interfering O
with O
protein B-NEU
synthesis I-NEU
. O

The O
reduced O
metronidazole O
then O
covalently O
binds O
to O
DNA O
, O
disrupt O
its O
helical O
structure O
, O
inhibiting O
bacterial B-NEG
nucleic I-NEG
acid I-NEG
synthesis I-NEG
and O
resulting O
in O
bacterial B-NEU
cell I-NEU
death I-NEU
. O

Esomeprazole O
is O
a O
proton O
pump O
inhibitor O
that O
suppresses O
gastric B-NEU
acid I-NEU
secretion I-NEU
by O
specific O
inhibition O
of O
the O
H<sup>+</sup>/K<sup>+</sup>-ATPase O
in O
the O
gastric O
parietal O
cell O
. O

-DOCSTART- O

To O
resolve O
exterior O
, O
eliminate O
damp B-NEU
, O
relieve O
cough B-NEG
and O
calm O
asthma B-NEG
. O

-DOCSTART- O

Treatment O
of O
stroke B-NEG
with O
gurgling O
in O
the O
throat O
, O
deviation O
of O
the O
eye B-DNP
and O
the O
mouth B-DNP
, O
and O
impairment B-NEG
of O
speech O
, O
upward O
invasion O
of O
phlegm B-NEG
causing O
headache B-NEG
accompanied O
with O
dizziness B-NEG
, O
heaviness B-NEG
of O
the O
body O
, O
restlessness B-NEG
, O
fidgetness B-NEG
, O
nausea B-NEG
and O
cold B-NEG
extremities O
, O
or O
migraine B-NEG
, O
sore B-NEG
throat I-NEG
, O
tetanus B-NEG
, O
external O
use O
for O
scrofula B-NEG
, O
venomous B-NEG
snake I-NEG
bite I-NEG
. O

-DOCSTART- O

Hepatitis B-NEG
C I-NEG
, O
Chronic O

-DOCSTART- O

Treatment O
of O
amenorrhea B-NEG
with O
mass B-NEG
in I-NEG
the I-NEG
abdomen I-NEG
, O
swelling B-NEG
of I-NEG
breast I-NEG
after O
childbirth O
, O
rubella B-NEG
red O
in O
colour O
, O
itching B-NEG
, O
acne B-NEG
. O

-DOCSTART- O

hematuria B-NEG
with O
pain B-NEG
; O
stranguria B-NEG
with O
hematuria B-NEG
; O
painful O
urination B-NEG
with I-NEG
blood I-NEG

-DOCSTART- O

abdominal B-NEG
mass I-NEG
; O
accumulation O

-DOCSTART- O

epiphora B-NEG
; O
lacrimation B-NEG

-DOCSTART- O

having O
painful O
and O
benumbed O
joint B-DNP

-DOCSTART- O

To O
relax O
the O
bowels B-DNP
( O
sthenia-syndrome B-NEG
with O
constipation B-NEG
due O
to O
accumulation O
of O
cold B-NEG
, O
dysentery B-NEG
of I-NEG
cold I-NEG
type O
) O
. O

-DOCSTART- O

Statin O
Therapy O

-DOCSTART- O

Hyperkalemia B-NEG

-DOCSTART- O

weakness B-NEG
of I-NEG
the I-NEG
waist I-NEG

-DOCSTART- O

To O
strengthen O
spleen B-DNP
and O
benefit O
dampness B-NEU
; O

To O
kill O
worms B-NEG
and O
stop O
diarrhea B-NEG

-DOCSTART- O

illness B-NEG
that O
occurs O
on O
teeth O

-DOCSTART- O

dryness B-NEU
of O
mouth O

-DOCSTART- O

Other O
Nutritional B-NEG
Deficiencies I-NEG

-DOCSTART- O

Ascites O
. O
Croton O
seed O
( O
Badou O
) O
is O
used O
with O
Apricot O
seed O
( O
Xingren O
) O
. O

-DOCSTART- O

a O
symptom O
of O
fingers O
being O
cold B-NEG
although O
the O
temperature O
is O
not O

-DOCSTART- O

Croton O
seed O
( O
Badou O
) O
is O
used O
externally O
. O

-DOCSTART- O

Shosaikoto O
, O
which O
is O
one O
of O
the O
Japanese O
and O
Chinese O
traditional O
herbal O
medicine O
mixtures O
, O
has O
several O
immunomodulating B-NEU
activities I-NEU
. O

Especially O
, O
Shosaikoto O
is O
a O
potent O
polyclonal O
B O
cell O
mitogen O
in O
vivo O
and O
in O
vitro O
. O

In O
order O
to O
characterize O
the O
active O
substances O
for O
mitogenic B-NEU
activity I-NEU
, O
Shosaikoto O
was O
fractionated O
by O
means O
of O
ethanol O
precipitation O
to O
give O
two O
fractions O
, O
called O
ethanol-precipitate O
( O
EP O
) O
fraction O
and O
ethanol-soluble O
( O
ES O
) O
fraction O
. O

The O
EP O
fraction O
consisted O
mainly O
of O
polysaccharides O
and O
showed O
significant O
mitogenic B-NEU
activity I-NEU
. O

The O
ES O
fraction O
consisted O
of O
low O
molecular O
compounds O
and O
did O
not O
show O
the O
activity O
in O
vitro O
. O

The O
EP O
fraction O
of O
hot O
water O
extracts O
of O
Glycyrrhizae O
Radix O
and O
Bupureuri O
Radix O
showed O
the O
activities O
, O
and O
the O
ES O
fraction O
of O
a O
hot O
water O
extract O
of O
Glycyrrhizae O
Radix O
and O
all O
fractions O
of O
hot O
water O
extract O
of O
Scutellariae O
Radix O
showed O
the O
cytotoxicity B-NEG
. O

These O
results O
suggested O
that O
the O
crude O
polysaccharide O
fractions O
could O
play O
an O
important O
role O
in O
the O
mitogenic B-NEU
activity I-NEU
by O
Shosaikoto O
. O

-DOCSTART- O

Therapeutic O
effect O
of O
Kakkonto O
in O
a O
mouse O
model O
of O
food O
allergy B-NEG
with O
gastrointestinal O
symptoms O
. O

-DOCSTART- O

Schizophrenia B-NEG
Prodrome I-NEG

-DOCSTART- O

hemiplegia B-NEG
; O

paralysis B-NEG

-DOCSTART- O

accumulation O
of O
pathogenic B-NEG
factors I-NEG
in I-NEG
the I-NEG
chest I-NEG
; O
accumulation O
of O
pathogens B-NEG
in I-NEG
the I-NEG
chest I-NEG
; O
knotted B-NEG
chest I-NEG
a O
syndrome O
due O
to O
accumulation O
of O
pathogenic B-NEG
heat I-NEG
or I-NEG
cold I-NEG
with O
stagnancy B-NEG
of I-NEG
fluid I-NEG
or O
phlegm B-NEG
or O
blood B-DNP
in O
the O
chest O
. O

-DOCSTART- O

To O
activate O
blood B-NEU
circulation I-NEU
, O
eliminate O
stasis B-NEG
, O
promote O
the O
subsidence B-POS
of I-POS
swelling I-POS
and O
alleviate O
pain B-NEG
. O

-DOCSTART- O

This O
is O
a O
syndrome O
with O
a O
pain B-NEG
, O
bloat B-NEU
, O
and O
fullness B-NEU
in O
abdominal O
region O
. O

-DOCSTART- O

tonify O
the O
kidney B-DNP

-DOCSTART- O

hoarseness B-NEG
due O
to O
singing O

-DOCSTART- O

To O
kill O
worms O
. O

-DOCSTART- O

Pralnacasan O
inhibits O
interleukin-1beta B-DNP
converting I-DNP
enzyme I-DNP
( O
ICE O
) O
, O
an O
enzyme O
that O
regulates O
the O
production O
of O
IL-1 B-DNP
and O
IFN B-DNP
gamma I-DNP
- O
intercellular O
mediators O
that O
initiate O
and O
sustain O
the O
process O
of O
inflammation O
. O
Inhibiting O
ICE O
may O
be O
an O
effective O
strategy O
for O
curtailing O
damaging O
inflammatory O
processes O
common O
to O
a O
number O
of O
acute O
and O
chronic O
conditions O
, O
such O
as O
rheumatoid B-NEG
arthritis I-NEG
( O
RA B-NEG
) O
and O
osteoarthritis B-NEG
. O

-DOCSTART- O

To O
dispel O
wind B-NEG
and O
relieve O
pain B-NEG
, O
kill O
worms O
and O
relieve O
itch O
, O
resolve B-NEG
toxin I-NEG
and O
close O
sores B-NEG
. O

-DOCSTART- O

This O
means O
urolithiasis B-NEG
made O
of O
coagulation B-NEG
of I-NEG
phlegm I-NEG
. O

-DOCSTART- O

A O
symptom O
that O
Gi O
gets O
together O
and O
blood B-DNP
does O
not O
circulate O
well O
. O

An O
affected O
part O
has O
abdominal B-NEG
distension I-NEG
or O
a O
sore B-NEG
. O

If O
it O
keeps O
long O
, O
it O
becomes O
blood B-NEG
stagnation I-NEG
, O
and O
causes O
a O
hard B-NEG
swelling I-NEG
and O
a O
serious O
pain B-NEG
on O
the O
part O
. O

-DOCSTART- O

To O
replenish O
yin O
of O
the O
lung B-DNP
and O
stomach B-DNP
, O
remove O
heat B-NEU
from I-NEU
the I-NEU
lung I-NEU
, O
and O
promote O
fluid B-NEU
secretion I-NEU
. O

-DOCSTART- O

Familial B-NEG
Adenomatous I-NEG
Polyposis I-NEG

-DOCSTART- O

( O
1 O
) O
/ O
/ O
morbid B-NEG
leukorrhea I-NEG
; O
( O
2 O
) O
gynecological B-NEG
diseases(in I-NEG
a O
broad O
sense O
) O

-DOCSTART- O

Treatment O
of O
scrotal B-NEG
hernia I-NEG
with O
pain B-NEG
and O
cold B-NEG
extremities I-NEG
, O
dysmenorrhea B-NEG
with O
lower O
abdominal B-NEG
pain I-NEG
and O
cold B-NEG
sensation I-NEG
, O
distending B-NEG
pain I-NEG
in I-NEG
the I-NEG
epigastrium I-NEG
with O
anorexia B-NEG
, O
vomiting B-NEG
and O
diarrhea B-NEG
, O
hydrocele B-NEG
of O
tunica O
vaginalis O
. O

Fructus O
Foeniculi O
( O
processed O
with O
salt O
) O
: O
Scrotal B-NEG
hernia I-NEG
with O
pain B-NEG
and O
cold B-NEG
extremities I-NEG
, O
dysmenorrhea B-NEG
with O
abdominal B-NEG
pain I-NEG
caused O
by O
cold B-NEG
. O

-DOCSTART- O

This O
is O
a O
syndrome O
that O
children O
wet O
their O
pants O
regardless O
of O
time O
. O

-DOCSTART- O

Protective B-NEU
immunity I-NEU
, O
Others O
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Others O
health I-DNP
and O
immunity B-NEU
, O
Metabolism B-NEU

-DOCSTART- O

Binding O
of O
dalbavancin O
to O
the O
D-Ala-D-Ala O
prevents O
the O
incorporation O
of O
the O
NAM/NAG-peptide O
subunits O
into O
the O
peptidoglycan O
matrix O
. O

-DOCSTART- O

promote O
sweating B-NEU

-DOCSTART- O

Stagnation O
of O
qi O
in O
the O
liver O
and O
the O
stomach O
marked O
by O
distending O
pain B-NEG
in O
the O
epigastrium O
, O
feeling O
of O
stuffiness B-NEG
and O
fullness B-NEU
in O
the O
chest O
, O
anorexia B-NEG
, O
belching B-NEG
and O
acid B-NEG
regurgitation I-NEG
. O

-DOCSTART- O

sudden O
turmoil B-NEG
; O

cholera B-NEG
disease I-NEG
; O

acute B-NEG
gastroenteritis I-NEG
; O

acute B-NEG
vomiting I-NEG
and O
diarrhea B-NEG
a O
group O
of O
diseases B-NEG
including O
cholera B-NEG
, O
characterized O
by O
sudden O
and O
drastic O
vomiting B-NEG
and O
diarrhea B-NEG
. O

-DOCSTART- O

To O
relieve O
exterior B-NEG
syndrome I-NEG
. O

-DOCSTART- O

Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
Blood B-NEU
pressure I-NEU

-DOCSTART- O

To O
dispel O
wind B-NEG
and O
relieve O
pain B-NEG
, O
soothe O
sinews B-DNP
and O
quicken O
network B-DNP
vessels I-DNP
. O

-DOCSTART- O

To O
cause O
catharsis O
and O
purge O
away O
heat B-NEU
, O
to O
reduce O
heat B-NEU
in O
blood B-DNP
and O
counteract O
toxicity B-NEG
, O
and O
to O
eliminate O
blood B-DNP
stasis I-DNP
and O
stimulate O
menstrual B-DNP
discharge I-DNP
. O

-DOCSTART- O

Its O
alcoholic O
extract O
inhibits O
the O
heart B-DNP
and O
lowers O
blood B-NEU
pressure I-NEU
in O
anesthetized O
cats O
. O

-DOCSTART- O

1 O
Its O
purgative O
effect O
is O
as O
three O
times O
as O
castor O
oil O
. O
2 O
. O
Its O
fresh O
preparation O
may O
inhibit O
the O
progress O
of O
acute B-NEG
lymphatic I-NEG
leukemia I-NEG
, O
acute B-NEG
and I-NEG
chronic I-NEG
granulocytic I-NEG
leukemia I-NEG
and O
acute B-NEG
monocytic I-NEG
leukemia I-NEG
. O

-DOCSTART- O

alleviate O
edema B-NEG
and O
relieve O
toxicity B-NEG

-DOCSTART- O

hoarseness B-NEG

-DOCSTART- O

Svere O
nodular B-NEG
acne I-NEG

-DOCSTART- O

stranguria B-NEG
due O
to O
heat B-NEU
; O
heat-type O
stranguria B-NEG

-DOCSTART- O

For O
activating O
blood B-DNP
and O
modulating O
period O

-DOCSTART- O

Hemodialysis B-NEG

-DOCSTART- O

Obesity B-NEG
and O
Obesity-related O
Medical O
Conditions O

-DOCSTART- O

irritability B-NEG
and O
restlessness B-NEG
; O

dysphoria B-NEG

-DOCSTART- O

Follicular B-NEG
Lymphoma I-NEG

-DOCSTART- O

constipation B-NEG

-DOCSTART- O

To O
dissipate O
cold B-NEG
and O
relieve O
pain B-NEG
, O
rectify O
qi O
and O
regulate O
center O
. O

-DOCSTART- O

Loratadine O
is O
a O
second-generation O
H1 O
histamine B-DNP
antagonist O
drug O
and O
appears O
to O
suppress O
the O
release O
of O
histamine B-DNP
and O
leukotrienes O
from O
mast O
cells O
, O
and O
the O
release O
of O
leukotrienes O
from O
human O
lung B-DNP
fragments O
. O

-DOCSTART- O

Liver B-DNP
health I-DNP
, O
Liver O
. O

-DOCSTART- O

Wind-cold B-NEG
common B-NEG
cold I-NEG
, O
headache O
, O
cough B-NEG
and O
asthma B-NEG
, O
deep-source O
nasal B-NEG
congestion I-NEG
, O
cold B-NEG
pain I-NEG
in O
stomach O
duct O
and O
abdomen O
, O
wind-cold-damp B-NEG
impediment I-NEG
, O
cold-damp B-NEG
vaginal B-NEG
discharge I-NEG
, O
dysmenorrhea B-NEG
, O
toxin B-NEG
swelling I-NEG
of O
sores B-NEG
, O
wind B-NEG
papule I-NEG
itching I-NEG
. O

-DOCSTART- O

tonify O
the O
bladder B-DNP

-DOCSTART- O

inflammation B-NEG
of O
the O
throat O
; O
sore B-NEG
throat I-NEG
; O
hoarse B-NEG
voice I-NEG
; O
aphonia B-NEG

-DOCSTART- O

This O
is O
a O
syndrome O
with O
ooze O
from O
a O
sore B-NEG
. O

-DOCSTART- O

OBJECTIVE O
: O
The O
purpose O
of O
this O
clinical O
trial O
was O
to O
assess O
the O
efficacy O
of O
Goshuyuto O
, O
a O
typical O
Kampo O
formula O
, O
in O
preventing O
episodes O
of O
headache B-NEG
in O
chronic B-NEG
headache I-NEG
patients O
. O

RESEARCH O
DESIGN O
AND O
METHODS O
: O
Because O
the O
treatment O
target O
of O
a O
Kampo O
formula O
is O
decided O
on O
a O
basis O
different O
to O
that O
of O
Western O
medicine O
, O
we O
first O
selected O
patients O
belonging O
to O
a O
subgroup O
that O
responded O
to O
goshuyuto O
before O
conducting O
the O
usual O
randomized O
controlled O
trial O
. O

During O
stage O
1, O
the O
subjects O
were O
instructed O
to O
orally O
consume O
goshuyuto O
for O
4 O
weeks O
. O

Only O
those O
subjects O
judged O
as O
responders O
advanced O
to O
stage O
2, O
during O
which O
a O
double-blind O
, O
randomized O
, O
placebo-controlled O
study O
was O
conducted O
. O

The O
subjects O
consumed O
the O
same O
dose O
of O
goshuyuto O
or O
placebo O
for O
12 O
weeks O
. O

RESULTS O
: O
Of O
the O
91 O
subjects O
enrolled O
in O
stage O
1, O
60 O
were O
judged O
as O
responders O
. O

Of O
these O
, O
53 O
advanced O
to O
stage O
2; O
28 O
were O
assigned O
to O
the O
goshuyuto O
group O
and O
25 O
to O
the O
placebo O
group O
. O

The O
decrease O
in O
the O
number O
of O
days O
on O
which O
headache B-NEG
episodes O
occurred O
was O
greater O
in O
the O
goshuyuto O
group O
than O
in O
the O
placebo O
group O
( O
2.6 O
+/- O
3.7 O
vs O
. O
0.3 O
+/- O
4 O
days O
, O
p O
= O
0.034 O
) O
; O
no O
difference O
was O
observed O
with O
regard O
to O
the O
reduction O
in O
the O
frequency O
of O
consuming O
reliever O
medications O
( O
2.2 O
+/- O
4 O
vs O
. O
1.4 O
+/- O
8.2 O
, O
p O
= O
0.672 O
) O
. O

Improvement O
in O
the O
associated O
symptoms O
was O
observed O
in O
more O
than O
0.5 O
of O
the O
subjects O
in O
the O
goshuyuto O
group O
. O

CONCLUSION O
: O
Goshuyuto O
is O
useful O
in O
preventing O
episodes O
of O
headache B-NEG
in O
chronic B-NEG
headache I-NEG
patients O
. O

Responder-limited O
design O
is O
a O
candidate O
for O
evaluating O
Kampo O
medicine O
. O

-DOCSTART- O

cough B-NEG
due O
to O
pulmonary B-NEG
flaccidity I-NEG

-DOCSTART- O

Paclitaxel O
interferes O
with O
the O
normal O
function B-NEU
of I-NEU
microtubule I-NEU
growth I-NEU
. O

Whereas O
drugs O
like O
colchicine O
cause O
the O
depolymerization B-NEU
of I-NEU
microtubules I-NEU
in O
vivo O
, O
paclitaxel O
arrests O
their O
function O
by O
having O
the O
opposite O
effect O
; O

it O
hyper-stabilizes O
their O
structure O
. O

This O
destroys O
the O
cell's O
ability O
to O
use O
its O
cytoskeleton O
in O
a O
flexible O
manner O
. O

Specifically O
, O
paclitaxel O
binds O
to O
the O
; O

subunit O
of O
tubulin O
. O

Tubulin O
is O
the O
building O
block O
of O
mictotubules O
, O
and O
the O
binding O
of O
paclitaxel O
locks O
these O
building O
blocks O
in O
place O
. O

The O
resulting O
microtubule O
/ O
paclitaxel O
complex O
does O
not O
have O
the O
ability O
to O
disassemble O
. O

This O
adversely O
affects O
cell O
function O
because O
the O
shortening O
and O
lengthening O
of O
microtubules O
( O
termed O
dynamic O
instability O
) O
is O
necessary O
for O
their O
function O
as O
a O
transportation O
highway O
for O
the O
cell O
. O

Chromosomes O
, O
for O
example O
, O
rely O
upon O
this O
property O
of O
microtubules O
during O
mitosis O
. O

Further O
research O
has O
indicated O
that O
paclitaxel O
induces O
programmed O
cell B-POS
death I-POS
( I-POS
apoptosis I-POS
) I-POS
in I-POS
cancer I-POS
cells I-POS
by O
binding O
to O
an O
apoptosis B-NEU
stopping O
protein O
called O
Bcl-2 O
( O
B-cell O
leukemia O
2 O
) O
and O
thus O
arresting O
its O
function O
. O

-DOCSTART- O

Quality O
of O
life O
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Others O
, O
Protective B-NEU
immunity I-NEU
, O
Inflammation B-NEG

-DOCSTART- O

The O
resin O
is O
a O
strong O
anion O
exchange O
resin O
, O
which O
means O
that O
it O
can O
exchange O
its O
chloride O
anions O
with O
anionic O
bile O
acids O
in O
the O
gastrointestinal O
tract O
and O
bind O
them O
strongly O
in O
the O
resin O
matrix O
. O

-DOCSTART- O

Advanced B-NEG
Breast I-NEG
Cancer I-NEG

-DOCSTART- O

Pregnancy B-NEG
in I-NEG
Diabetics I-NEG

-DOCSTART- O

miasma B-NEG
1 O
pestilential B-NEG
pathogene B-NEG
2 O
malaria O

-DOCSTART- O

To O
dispel O
wind-heat B-NEG
, O
to O
promote O
eruption B-NEG
, O
and O
to O
cause O
diuresis B-NEU
. O

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
Body B-NEU
weight I-NEU
regulation I-NEU
, O
Digestion O
, O
Energy O
/ O
food O
intake O
( O
apetite O
/ O
satiety O
) O
, O
Physical B-DNP
performance B-DNP
and O
fitness B-POS
, O
Body B-NEU
fat I-NEU
deposition I-NEU
( O
total O
amount O

-DOCSTART- O

To O
cool O
blood B-DNP
and O
stanch B-POS
bleeding I-POS
, O
quicken O
blood B-DNP
and O
transform O
stasis O
. O

-DOCSTART- O

affection O
by O
summer O
heat O
; O
exposure O
to O
summer O
heat O

-DOCSTART- O

A O
74-year-old O
man O
was O
admitted O
to O
our O
hospital O
complaining O
of O
severe O
neck B-NEG
pain I-NEG
and O
general O
fatigue B-NEG
. O

He O
had O
been O
undergoing O
treatment O
for O
post-operative O
neck B-NEG
pain I-NEG
at O
the O
out-patient O
clinic O
of O
our O
hospital O
, O
but O
was O
now O
complaining O
of O
pain O
more O
intense O
than O
usual O
. O

Chest O
X-rays O
revealed O
diffuse O
ground O
glass O
shadows O
in O
bilateral O
lung O
fields O
, O
and O
computed O
tomography O
revealed O
diffuse O
intestinal O
shadows O
. O

A O
drug O
lymphocyte O
stimulation O
test O
( O
DLST O
) O
was O
also O
performed O
at O
that O
time O
. O

Steroid O
pulse O
therapy O
improved O
the O
clinical O
symptoms O
, O
hypoxemia B-NEG
and O
chest O
X-ray O
findings O
. O

DLST O
performed O
again O
with O
Yokukansan O
and O
Hachimijiogan O
133 O
days O
after O
the O
initial O
diagnosis O
of O
pneumonitis O
showed O
Yokukansan O
was O
positive O
. O

This O
result O
showed O
Yukukansan O
may O
be O
a O
causative O
drug O
for O
allergic O
drug-induced O
pneumonitis B-NEG
. O

Any O
drugs O
including O
kanpo O
may O
be O
possible O
to O
induce O
allergic O
pneumonitis B-NEG
. O

-DOCSTART- O

Cold B-NEG
pain I-NEG
in O
stomach O
duct O
and O
abdomen O
, O
indigestion B-NEG
, O
vomiting B-NEG
nausea B-NEG
, O
diarrhea B-NEG
, O
cold B-NEG
mounting O
, O
dysmenorrhea B-NEG
, O
urethral B-NEG
stone I-NEG
, O
swelling B-NEG
pain I-NEG
of O
sore O
and O
boil O
. O

-DOCSTART- O

Simvastatin O
competitively O
inhibits O
HMG-CoA O
reductase O
, O
lowers O
plasma B-NEU
cholesterol I-NEU
and O
lipoprotein B-NEU
levels I-NEU
, O
and O
modulates O
immune B-NEU
responses I-NEU
by O
suppressing O
MHC O
II O
on O
interferon O
gamma-stimulated O
, O
antigen-presenting B-DNP
cells I-DNP
such O
as O
human B-DNP
vascular I-DNP
endothelial I-DNP
cells I-DNP
. O
Sitagliptin O
is O
a O
highly O
selective O
DPP-4 O
inhibitor O
, O
and O
increases O
insulin B-NEU
release I-NEU
and O
decreases O
glucagon B-NEU
levels I-NEU
in O
the O
circulation O
in O
a O
glucose-dependent O
manner O
. O

-DOCSTART- O

To O
clear O
heat B-NEU
and O
remove O
toxic B-NEG
materials I-NEG
; O
To O
tonify O
kidney B-DNP
and O
revitalize O
blood B-DNP

-DOCSTART- O

( O
1 O
) O
pain B-NEG
in O
the O
abdomen O
and O
below O
the O
xyphoid O
process O
( O
2 O
) O
upper B-NEG
abdominal I-NEG
pain I-NEG

-DOCSTART- O

Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Reproductive B-DNP
systems I-DNP
, O
Dermatological B-DNP
systems I-DNP
health I-DNP
, O
Overall O
CVD B-NEG
, O
Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
General O
skin B-DNP
health I-DNP
, O
Others O

-DOCSTART- O

1 O
Application O
to O
cass O
of O
early O
stage O
of O
superficial O
pyogenic O
infection O
with O
local O
signs O
of O
inflammation B-NEG
, O
chilliness B-NEG
, O
fever B-NEG
, O
bitter B-NEG
mouth I-NEG
, O
constipation B-NEG
, O
oliguria B-NEG
, O
red B-NEG
tongue I-NEG
with O
white O
fur O
and O
rapid B-NEU
pulse I-NEU
. O
2 O
Also O
indicated O
for O
cases O
of O
urticaria B-NEG
and O
e O

-DOCSTART- O

arrest O
cough B-NEG
and O
relieve O
asthms B-NEG

-DOCSTART- O

This O
is O
a O
syndrome O
after O
phlegm B-NEG
due O
to O
Wind O
sidesae O
blocked O
Gi O
. O

-DOCSTART- O

Protective B-NEU
immunity I-NEU
, O
Urinary B-DNP
systems I-DNP
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Urinary B-DNP
system I-DNP
health I-DNP

-DOCSTART- O

Postpartum O
bleeding B-NEG
, O
migraine B-NEG
. O

-DOCSTART- O

Proellex O
selectively O
blocks B-DNP
the I-DNP
progesterone I-DNP
receptor I-DNP
thus O
avoiding O
the O
adverse O
effects O
of O
GnRH O
agonists O
associated O
with O
the O
induction O
of O
a O
low O
estrogen B-DNP
, O
menopausal-like B-DNP
state O
in O
women O
. O

-DOCSTART- O

lingual B-NEG
pustule I-NEG
; O
boil B-NEG
of O
the O
tongue O

-DOCSTART- O

Sirolimus O
inhibits O
T O
lymphocyte O
activation O
and O
proliferation O
that O
occurs O
in O
response O
to O
antigenic O
and O
cytokine O
( O
Interleukin O
IL-2 O
, O
IL-4 O
, O
and O
IL-15 O
) O
stimulation O
by O
a O
mechanism O
that O
is O
distinct O
from O
that O
of O
other O
immunosuppressants O
. O

-DOCSTART- O

BACKGROUND O
: O
The O
diagnosis O
of O
encephalitis B-NEG
is O
usually O
presumptive O
based O
on O
MRI O
, O
cerebrospinal O
fluid O
analysis O
, O
or O
both O
. O

A O
definitive O
diagnosis O
based O
on O
histopathology O
, O
however O
, O
is O
required O
for O
optimizing O
treatment O
strategies O
. O

OBJECTIVE O
: O
To O
investigate O
the O
diagnostic O
yield O
and O
adverse O
effects O
of O
minimally O
invasive O
brain O
biopsies O
in O
dogs O
with O
encephalitis B-NEG
. O

ANIMALS O
: O
Seventeen O
dogs O
with O
suspected O
encephalitis B-NEG
, O
based O
on O
MR O
imaging O
and O
cerebrospinal O
fluid O
analysis O
. O

METHODS O
: O
Retrospective O
study O
. O

Minimally O
invasive O
, O
free-hand O
brain O
biopsy O
specimens O
were O
taken O
from O
forebrain O
lesions O
through O
a O
4-mm O
burr O
hole O
using O
a O
Sedan O
side-cutting O
needle O
. O

Routine O
histopathological O
examination O
was O
performed O
. O

The O
adverse O
effects O
were O
assessed O
by O
MRI O
evaluations O
after O
biopsy O
procedure O
( O
1217 O
) O
and O
by O
sequential O
neurological O
examinations O
. O

RESULTS O
: O
The O
overall O
diagnostic O
yield O
with O
regard O
to O
a O
specific O
type O
of O
encephalitis B-NEG
was O
0.82 O
. O

Encephalitis B-NEG
was O
evident O
in O
an O
additional O
0.12 O
, O
but O
a O
specific O
disease B-NEG
could O
not O
be O
determined O
. O

There O
were O
no O
deaths O
caused O
by O
the O
biopsy O
procedure O
itself O
, O
but O
the O
indirect O
case O
fatality O
rate O
was O
0.06 O
. O

Morbidity O
was O
0.29 O
, O
including O
stupor B-NEG
, O
seizures B-NEG
, O
tetraparesis B-NEG
, O
hemiparesis B-NEG
, O
ataxia B-NEG
, O
and O
loss O
of O
conscious O
proprioception O
. O

All O
these O
signs O
resolved O
within O
0314 O
days O
. O

CONCLUSIONS O
AND O
CLINICAL O
IMPORTANCE O
: O
Minimally O
invasive O
brain O
biopsy O
in O
dogs O
with O
suspected O
encephalitis O
leads O
to O
a O
definite O
diagnosis O
in O
the O
majority O
of O
dogs O
, O
allowing O
for O
a O
specific O
treatment O
. O

The O
advantages O
of O
a O
definite O
diagnosis O
outweigh O
potential O
case O
fatality O
rate O
and O
temporary O
neurological B-NEG
deficits I-NEG
. O

-DOCSTART- O

abdominal B-NEG
distension I-NEG
; O
distension B-NEG
of I-NEG
abdomen I-NEG
with O
a O
gas O
or O
fluid O

-DOCSTART- O

malignant O
furuncle B-NEG
due O
to O
scrofula B-NEG
. O

-DOCSTART- O

relieve O
fever B-NEG

-DOCSTART- O

injury B-NEG
due O
to O
trauma B-NEG

-DOCSTART- O

Exenatide O
is O
a O
functional O
analog O
of O
the O
human O
incretin O
Glucagon-Like O
Peptide-1 O
( O
GLP-1 O
) O
. O

Incretins O
enhance O
glucose-dependent B-NEU
insulin I-NEU
secretion I-NEU
and O
exhibit O
other O
antihyperglycemic O
actions O
following O
their O
release O
into O
the O
circulation O
from O
the O
gut O
. O

The O
GLP-1 O
system O
increases O
insulin B-NEU
secretion I-NEU
only O
in O
the O
presence O
of O
elevated O
plasma O
glucose O
levels O
, O
avoiding O
inappropriately O
high B-NEG
insulin I-NEG
levels I-NEG
during O
fasting O
. O

The O
drug O
also O
moderates O
peak O
serum B-NEU
glucagon I-NEU
levels I-NEU
during O
hyperglycemic O
periods O
following O
meals O
, O
but O
does O
not O
interfere O
with O
glucagon B-NEU
release I-NEU
in O
response O
to O
hypoglycemia O
. O

Secondary O
effects O
of O
drug O
administration O
reduces O
the O
rate B-NEU
of I-NEU
gastric I-NEU
emptying O
and O
decreases O
food B-NEU
intake I-NEU
, O
mitigating O
the O
potential O
severity O
of O
hyperglycemic O
events O
after O
meals O
. O

-DOCSTART- O

swelling B-NEG
of O
the O
foot O
; O
edema B-NEG
of O
foot O

-DOCSTART- O

Boils O
and O
carbuncles O
. O

-DOCSTART- O

incised B-NEG
wound I-NEG

-DOCSTART- O

Hypogonadotropic B-NEG
Hypogonadism I-NEG

-DOCSTART- O

boil B-NEG
in I-NEG
the I-NEG
throat I-NEG

-DOCSTART- O

Treatment O
of O
: O
1 O
Deficient O
yin O
of O
the O
lungs B-DNP
with O
heat B-NEU
manifested O
as O
dry B-NEG
cough I-NEG
or O
cough B-NEG
with O
scanty O
sputum B-NEG
, O
hoarse B-NEG
voice I-NEG
from O
a O
chronic B-NEG
cough I-NEG
, O
dry B-NEU
throat I-NEU
and O
thirst B-NEU
. O

Glehnia O
root O
( O
Shashen O
) O
is O
used O
with O
Ophiopogon O
root O
( O
Maidong O
) O
and O
Tendrilled O
fritillary O
bulb O
( O
Chuanbeimu O
) O
. O

2 O
Body O
fluids O
consumed O
by O
febrile B-NEG
diseases I-NEG
manifested O
as O
dry B-NEG
tongue I-NEG
and O
poor B-NEG
appetite I-NEG
. O

Glehnia O
root O
( O
Shashen O
) O
is O
used O
with O
Ophiopogon O
root O
( O
Maidong O
) O
, O
Fresh O
rehmannia O
root O
( O
Shengdihuang O
) O
and O
Fragrant O
solomonseal O
rhizome O
( O
Yuzhu O
) O
in O
the O
formula O
Yiwei O
Tang O
. O

-DOCSTART- O

dry O
phlegm B-DNP
; O
dry-phlegm B-NEG
( O
syndrome O
) O

-DOCSTART- O

infantile B-NEG
malnutrition I-NEG
an O
infantile B-NEG
disease I-NEG
due O
to O
digestive B-NEG
disturbance I-NEG
or O
intestinal B-NEG
parasites I-NEG
with O
symptoms O
of O
wasting O
, O
pallor B-NEG
or O
sallowness B-NEG
, O
potbelly B-NEG
, O
and O
chronic B-NEG
diarrhea I-NEG
. O

-DOCSTART- O

promote O
liquid O

-DOCSTART- O

hemoptysis B-NEG
; O
coughing O
up O
blood B-NEU

-DOCSTART- O

To O
eliminate O
toxic B-NEG
material I-NEG
, O
promote O
pus B-POS
drainage I-POS
and O
remove O
blood B-NEG
stasis I-NEG
. O

-DOCSTART- O

Eyebrow B-NEG
Hypotrichosis I-NEG

-DOCSTART- O

distribution O
) O
, O
absorption B-NEU
, O
Endurance B-NEU
, O
Body B-NEU
weight I-NEU
, O
energy O
supply O
and O
recovery B-POS
, O
Mimmuietabolic B-NEU
rate I-NEU
/ I-NEU
energy I-NEU
expenditure I-NEU
, O
motility B-NEU
, O
Others O

-DOCSTART- O

spontaneous B-NEG
sweating(perspiration I-NEG
) O
frequent B-NEG
sweating I-NEG
due O
to O
lowered O
superficial O
resistance O
brought O
on O
by O
deficiency B-NEG
of O
Gi O
. O

-DOCSTART- O

To O
dispel O
wind B-NEG
and O
free O
network B-DNP
vessels I-DNP
, O
disperse O
swelling B-NEG
and O
relieve O
pain B-NEG
, O
clear O
heat B-NEG
and O
resolve O
toxin B-NEG
. O

-DOCSTART- O

secure O
the O
essence O

-DOCSTART- O

G4544 O
reduces O
bone B-NEG
loss I-NEG
by O
inhibiting O
calcium B-NEU
resorption I-NEU
from I-NEU
bone I-NEU
. O

Preclinical O
evidence O
suggests O
that O
the O
mechanism O
of O
G4544 O
action O
is O
multifactorial O
and O
different O
from O
other O
current O
therapies O
used O
to O
treat O
bone B-NEG
loss I-NEG
, O
such O
as O
estrogen B-DNP
or O
selective O
estrogen O
receptor O
modulators O
( O
SERMs O
) O
, O
calcitonin O
, O
or O
bisphosphonates O
( O
e.g O
. O
, O
Zometa O
or O
Fosamax O
) O
. O

G4544 O
preferentially O
accumulates O
in O
metabolically O
active O
regions O
of O
bone O
, O
inhibits O
osteoclast-mediated B-NEU
bone I-NEU
resorption I-NEU
, O
and O
favorably O
alters O
bone O
mineral O
composition O
and O
properties O
. O

-DOCSTART- O

menorrhagia B-NEG
; O
abnormally O
profuse B-NEG
menstruation I-NEG

-DOCSTART- O

Indacaterol O
works O
by O
stimulating O
adrenergic B-DNP
beta-2 I-DNP
receptors I-DNP
in O
the O
smooth O
muscle O
of O
the O
airways O
. O

Tiotropium O
is O
a O
muscarinic O
receptor O
antagonist O
, O
often O
referred O
to O
as O
an O
antimuscarinic O
or O
anticholinergic O
agent O
. O

-DOCSTART- O

nocturnal B-NEU
emission I-NEU
; O
emission O
; O
spermatorrhea B-NEG
; O
seminal B-NEU
emission I-NEU

-DOCSTART- O

epistaxis B-NEG

-DOCSTART- O

Sabarubicin O
blocking O
of O
DNA O
replication O
reduced O
the O
counteractive O
activity O
of O
mutagenic O
translesional O
bypass O
replication O
across O
cisplatin-DNA O
adducts O
. O

-DOCSTART- O

thirst B-NEG
with O
fever B-NEG

-DOCSTART- O

Cough B-NEG
and O
asthma B-NEG
, O
fright O
epilepsy B-NEG
, O
wind-cold-damp B-NEG
impediment O
, O
dysentery B-NEG
, O
prolapse B-NEG
of I-NEG
rectum I-NEG
, O
knocks O
and O
falls O
. O

-DOCSTART- O

To O
tonify O
the O
spleen B-DNP
, O
to O
relieve O
diarrhea B-NEG
, O
to O
replenish O
the O
kidney B-DNP
, O
to O
arrest O
seminal B-NEU
emission I-NEU
, O
and O
to O
nourish O
the O
heart B-DNP
, O
to O
induce O
tranquillization B-NEU
. O

-DOCSTART- O

Wind-damp B-NEG
impediment O
pain B-NEG
, O
pain B-NEG
in O
stomach O
duct O
, O
wound O
swelling B-NEG
from O
knocks B-NEG
and O
falls B-NEG
, O
fracture B-NEG
, O
bleeding B-NEG
due O
to O
external O
injury B-NEG
. O

-DOCSTART- O

Glomerulonephritis B-NEG

-DOCSTART- O

Bofutsushosan O
( O
BOF O
) O
, O
a O
traditional O
Chinese O
formulation O
( O
Kampo O
formulation O
in O
Japanese O
) O
, O
is O
widely O
used O
for O
patients O
with O
obesity B-NEG
and O
hyperlipidemia B-NEG
resulting O
from O
long-term O
inappropriate O
lifestyles O
. O

Since O
atherosclerosis B-NEG
, O
a O
lifestyle-related B-NEG
disease I-NEG
, O
is O
accompanied O
by O
an O
abnormal O
accumulation O
of O
vascular B-DNP
smooth I-DNP
muscle I-DNP
cells I-DNP
( O
VSMCs B-DNP
) O
in O
the O
intimal O
area O
of O
the O
artery O
, O
we O
investigated O
the O
preventive O
effect O
of O
BOF O
on O
intimal O
thickening O
. O

Oral O
administration O
of O
BOF O
extracts O
3 O
d O
before O
and O
7 O
d O
after O
balloon O
endothelial O
denudation O
dose O
dependently O
suppressed O
the O
intimal O
thickening O
and O
proliferation O
of O
VSMCs B-DNP
in O
the O
intimal O
area O
in O
rat O
carotid O
arteries O
. O

This O
model O
has O
a O
similar O
pathologic O
process O
to O
atherosclerosis B-NEG
and O
is O
considered O
to O
be O
an O
accelerated O
atherosclerosis B-NEG
model O
. O

BOF O
extract O
also O
dose O
dependently O
inhibited O
the O
migration O
of O
cultured O
VSMCs B-DNP
. O

BOF O
extract O
suppressed O
serum B-DNP
lipid O
levels O
, O
which O
are O
a O
major O
risk O
factor O
for O
atherosclerosis B-NEG
. O

These O
findings O
clarified O
the O
usefulness O
of O
BOF O
in O
cardiovascular O
risk-reduction O
therapy O
. O

-DOCSTART- O

Menstrual B-NEG
disorder I-NEG
, O
postpartum B-NEG
abdominal I-NEG
pain I-NEG
due O
to O
stasis B-NEG
obstruction I-NEG
, O
knocks B-NEG
and O
falls B-NEG
, O
wind-damp B-NEG
impediment I-NEG
pain I-NEG
. O

-DOCSTART- O

To O
soothe O
the O
liver B-DNP
and O
regulate O
the O
circulation O
of O
qi O
, O
clear O
away O
heat B-NEU
and O
toxic B-NEG
materials I-NEG
. O

-DOCSTART- O

warm O
the O
bladder O

-DOCSTART- O

neck B-NEG
stiffness I-NEG
; O
neck B-NEG
rigidity I-NEG
; O
rigidity B-NEG
of I-NEG
the I-NEG
neck I-NEG
; O
rigid B-NEG
neck I-NEG

-DOCSTART- O

BACKGROUND O
: O
Crohn's B-NEG
disease I-NEG
( O
CD B-NEG
) O
is O
a O
chronic B-NEG
inflammatory I-NEG
disease I-NEG
with O
increasing O
incidence O
in O
children O
. O

Current O
medications O
have O
potentially O
serious O
side O
effects O
, O
hence O
increasing O
interest O
in O
alternative O
therapies O
. O

We O
previously O
developed O
an O
herbal O
formula O
, O
FAHF-2 O
, O
based O
on O
a O
classical O
traditional O
Chinese O
herbal O
formula O
Wu O
Mei O
Wan O
that O
has O
long O
been O
used O
in O
China O
to O
treat O
colitis B-NEG
. O

We O
investigated O
FAHF-2's O
potential O
anti-inflammatory B-POS
effects O
. O

METHODS O
: O
FAHF-2 O
efficacy O
was O
tested O
in O
vivo O
in O
the O
CD45RbRAG1 O
transfer O
colitis O
model O
. O

Weight O
loss O
, O
colonic O
histology O
, O
and O
cytokine O
production O
from O
mesenteric O
lymph O
nodes O
were O
assessed O
. O

Human O
peripheral B-DNP
blood I-DNP
mononuclear I-DNP
cells I-DNP
( O
PBMCs B-DNP
) O
and O
colonic O
biopsies O
were O
obtained O
from O
children O
newly O
diagnosed O
with O
CD B-NEG
and O
controls O
and O
cultured O
with O
or O
without O
FAHF-2 O
. O

Cytokine B-NEU
levels I-NEU
were O
measured O
by O
multiplex O
immunoassay O
. O

The O
effect O
of O
FAHF-2 O
on O
TNF- B-NEU
- I-NEU
producing I-NEU
cells I-NEU
was O
determined O
by O
flow O
cytometry O
. O

NF-kB B-NEU
signaling I-NEU
was O
investigated O
in O
human O
lamina O
propria O
mononuclear O
cells O
upon O
FAHF-2 O
treatment O
by O
In-Cell O
Western O
. O

RESULTS O
: O
FAHF-2-treated O
mice O
had O
decreased O
weight O
loss O
, O
improved O
histology O
, O
and O
reduced O
TNF- B-DNP
, O
IL-17 B-DNP
, O
IL-6 B-DNP
, O
and O
IFN-y B-DNP
production O
. O

In O
vitro O
treated O
PBMCs B-DNP
produced O
less O
TNF- B-DNP
, O
IFN-y B-DNP
, O
and O
IL-12 B-DNP
. O

FAHF-2 O
reduced O
the O
TNF-a B-NEU
- I-NEU
producing I-NEU
monocytes O
and O
T B-DNP
cells I-DNP
. O

-DOCSTART- O

Ceftazidime O
inhibits O
the O
bacteria B-NEU
cell I-NEU
wall I-NEU
synthesis I-NEU
via O
affinity O
for O
penicillin-binding B-NEU
- I-NEU
binding I-NEU
proteins I-NEU
( O
PBPs B-NEU
) O
. O

The O
reduced O
metronidazole O
then O
covalently O
binds O
to O
DNA O
, O
disrupt O
its O
helical O
structure O
, O
inhibiting O
bacterial O
nucleic B-NEU
acid I-NEU
synthesis I-NEU
and O
resulting O
in O
bacterial O
cell B-NEU
death I-NEU
. O

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Digestion B-NEU
, O
Physical B-DNP
performance B-DNP
and O
fitness B-POS
, O
absorption B-NEU
, O
Lipid O
profile O
, O
Diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
Strength B-POS
and O
power B-POS
, O
Others O
, O
motility B-NEU

-DOCSTART- O

warm B-NEG
malaria I-NEG
; O

pyrexial B-NEG
malaria I-NEG

-DOCSTART- O

Wind-damp B-NEG
impediment O
pain B-NEG
, O
toothache B-NEG
, O
knee B-NEG
joint I-NEG
pain I-NEG
, O
scab B-NEG
and O
lichen B-NEG
, O
eczema B-NEG
, O
trichomoniasis B-NEG
, O
scalds B-NEG
, O
wound B-NEG
, O
enduring B-NEG
sores I-NEG
, O
bilharziosis B-NEG
, O
cough B-NEG
and O
asthma B-NEG
. O

-DOCSTART- O

Kidney B-NEG
Diseases I-NEG

-DOCSTART- O

moisten O
the O
lung B-DNP
and O
send O
Gi(Qi O
) O
downward O

-DOCSTART- O

General O
woman O
, O
Woman O
, O
Menopausal B-NEG
woman I-NEG

-DOCSTART- O

Relaxing O
the O
smooth O
muscles O
of O
blood B-DNP
vessels I-DNP
and O
stimulating O
those O
of O
uterus B-DNP
, O
urinary O
bladderl B-DNP
bronchus O
and O
gastrointestines B-DNP
. O

-DOCSTART- O

retention O
of O
the O
dead O
fetus O

-DOCSTART- O

This O
is O
a O
syndrome O
with O
throat B-NEG
pain I-NEG
due O
to O
Wind-Heat B-NEG
. O

It O
has O
red B-NEG
spots I-NEG
on O
all O
of O
the O
body O
, O
burning B-NEG
heat I-NEG
, O
difficulty O
in O
swallowing O
foods O
, O
headache B-NEG
, O
and O
aversion B-NEG
to O
cold O
. O

-DOCSTART- O

Purging B-POS

-DOCSTART- O

To O
nourish O
blood O
. O

-DOCSTART- O

Chinese O
herbal O
medicine O
( O
CHM O
) O
, O
either O
in O
single O
herb O
or O
in O
herbal O
formula O
, O
has O
been O
used O
to O
treat O
insomnia B-NEG
for O
more O
than O
2000 O
years O
. O

A O
systematic O
review O
including O
Chinese O
and O
English O
literature O
of O
randomized O
controlled O
trials O
was O
conducted O
to O
examine O
the O
efficacy O
, O
safety O
, O
and O
composition O
of O
CHM O
for O
insomnia B-NEG
. O

Among O
the O
217 O
studies O
we O
have O
reviewed O
, O
only O
eight O
had O
a O
Jadad O
score O
>= O
3, O
and O
seven O
out O
of O
these O
eight O
studies O
had O
at O
least O
one O
domain O
with O
high O
risks O
of O
bias O
. O

Meta-analyses O
of O
the O
studies O
with O
Jadad O
score O
>= O
3 O
found O
that O
CHM O
was O
similar O
to O
Western O
medication O
( O
three O
studies O
) O
and O
placebo O
( O
three O
studies O
) O
in O
treating O
insomnia B-NEG
. O

Due O
to O
the O
poor O
methodological O
quality O
of O
the O
studies O
and O
the O
small O
number O
of O
trials O
included O
in O
meta-analyses O
, O
the O
current O
evidence O
is O
insufficient O
to O
support O
the O
efficacy O
of O
CHM O
for O
insomnia B-NEG
. O

The O
frequency O
of O
adverse O
events O
associated O
with O
CHM O
was O
similar O
to O
that O
of O
placebo O
, O
but O
lower O
than O
with O
Western O
medication O
. O

Gui O
Pi O
Tang O
was O
the O
most O
commonly O
used O
standardized O
formula O
, O
while O
Suan O
Zao O
Ren O
( O
Ziziphus O
jujuba O
) O
was O
the O
most O
frequently O
used O
single O
herb O
. O

Further O
studies O
with O
a O
double-blind O
placebo-controlled O
design O
are O
needed O
to O
accurately O
determine O
the O
benefits O
and O
risks O
of O
CHM O
for O
insomnia B-NEG
. O

-DOCSTART- O

Vaginitis B-NEG

-DOCSTART- O

asthma B-NEG
and O
cough B-NEG

-DOCSTART- O

1 O
Applicable O
to O
cases O
of O
hypovolumic B-NEG
and I-NEG
cardiogenic I-NEG
shock I-NEG
which O
are O
attributed O
to O
exhaustion B-NEG
of O
primordial O
energy O
and O
yang-energy O
. O
2 O
Also O
applicable O
to O
cases O
of O
hemorrhagic B-NEG
shock I-NEG
attributed O
to O
yang O
depletion O
. O

-DOCSTART- O

Macular B-NEG
Degeneration I-NEG

-DOCSTART- O

promote O
menstruation B-DNP

-DOCSTART- O

Pseudoephedrine B-DNP
relaxes O
bronchial O
smooth O
muscle O
by O
stimulating O
beta2-adrenergic O
receptors O
. O

-DOCSTART- O

To O
benefit O
vital O
energy O
, O
lift O
yang O
and O
activate O
vital O
energy O
. O

-DOCSTART- O

Melphalan O
alkylates O
DNA O
at O
the O
N7 O
position O
of O
guanine O
and O
induces O
DNA O
inter-strand O
cross-linkages O
, O
resulting O
in O
the O
inhibition O
of O
DNA B-DNP
and I-DNP
RNA I-DNP
synthesis I-DNP
and O
cytotoxicity B-NEG
against O
both O
dividing O
and O
non-dividing O
tumor B-NEG
cells I-NEG
. O

-DOCSTART- O

Excessive O
Repair O

-DOCSTART- O

Drug B-NEG
Induced I-NEG
Hepatotoxicity I-NEG

-DOCSTART- O

To O
remove O
toxic B-NEG
heat I-NEG
, O
to O
soothe O
the O
sore B-NEG
throat I-NEG
, O
to O
resolve O
phlegm B-NEG
, O
and O
to O
relieve O
dysuria B-NEG
. O

-DOCSTART- O

It O
contains O
about O
50% O
of O
fatty O
oil O
, O
exerting O
antitussive B-POS
effect I-POS
. O

-DOCSTART- O

To O
remove O
toxic B-NEG
heat I-NEG
, O
to O
promote O
the O
drainage B-POS
of I-POS
pus I-POS
, O
and O
to O
relieve O
dysuria B-NEG
. O

-DOCSTART- O

This O
is O
a O
transmission O
of O
pathogenic O
factor O
of O
pyogenic B-NEG
febrile I-NEG
disease I-NEG
from O
Taeyanggyeong O
to O
Yangmyeonggyeong O
. O

-DOCSTART- O

To O
nourish O
yin O
and O
moisterize O
lung B-DNP
; O

To O
suppress O
fire O
and O
desolve O
phlegm B-NEG

-DOCSTART- O

replenish O
Gi(Qi O
) O
and O
invigorate O
the O
spleen B-DNP

-DOCSTART- O

Urinary B-DNP
system I-DNP
health I-DNP
, O
Urinary B-DNP
systems I-DNP

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Protective O
immunity B-NEU
, O
Others O

-DOCSTART- O

phlegm B-NEG
; O
sputum B-NEG
pathologic O
mucoid O
substances O
collected O
in O
a O
diseased O
organ O
or O
tissue O
. O

-DOCSTART- O

amenorrhea B-NEG

-DOCSTART- O

vomiting B-NEG
of O
milk O

-DOCSTART- O

dizziness B-NEG
and O
palpitation B-NEG
due O
to O
congested B-NEG
fluids I-NEG

-DOCSTART- O

Liquid O
chromatography-hydride O
generation-atomic O
fluorescence O
spectrometry O
determination O
of O
arsenic B-DNP
species I-DNP
in O
dog O
plasma O
and O
its O
application O
to O
a O
pharmacokinetic O
study O
after O
oral O
administration O
of O
Realgar O
and O
Niu O
Huang O
Jie O
Du O
Pian O
. O

-DOCSTART- O

Effects O
of O
Yokukansan O
, O
a O
traditional O
Japanese O
medicine O
, O
on O
thiamine B-NEG
deficiency I-NEG
( O
TD B-NEG
) O
- O
induced O
decrease O
of O
glutamate O
uptake O
were O
examined O
in O
cultured O
rat O
cortical O
astrocytes O
. O

Yokukansan O
( O
100-500 O
microg/ml O
) O
ameliorated O
the O
TD B-NEG
- O
induced O
decrease O
in O
glutamate O
uptake O
by O
astrocytes B-DNP
, O
implying O
that O
yokukansan O
may O
contain O
active O
herbs O
and O
compounds O
possessing O
this O
effect O
. O

Among O
the O
seven O
constituent O
herbs O
of O
yokukansan O
, O
significant O
effects O
were O
found O
for O
glycyrrhiza O
. O

Furthermore O
, O
glycyrrhizin O
and O
its O
metabolite O
18 O
beta-glycyrrhetinic O
acid O
( O
10(-7)-10(-4)M O
) O
, O
among O
the O
eight O
components O
of O
glycyrrhiza O
, O
ameliorated O
the O
TD B-NEG
- O
induced O
decrease O
of O
glutamate O
uptake O
in O
astrocytes O
in O
a O
concentration-dependent O
manner O
. O

These O
substances O
inhibited O
protein B-DNP
kinase I-DNP
C I-DNP
( O
PKC B-DNP
) O
activity O
under O
the O
in O
vitro O
conditions O
. O

These O
lines O
of O
evidence O
suggest O
that O
glycyrrhizin O
, O
a O
main O
component O
of O
glycyrrhiza O
, O
and O
its O
metabolite O
18 O
beta-glycyrrhetinic O
acid O
are O
likely O
responsible O
for O
amelioration O
of O
dysfunction O
of O
glutamate O
transport O
in O
astrocytes O
. O

The O
inhibition O
of O
the O
PKC B-NEU
activity I-NEU
might O
be O
related O
to O
the O
pharmacological O
efficacy O
of O
these O
substances O
. O

-DOCSTART- O

Zidovudine O
inhibits O
the O
activity B-NEG
of I-NEG
HIV-1 I-NEG
reverse I-NEG
transcriptase I-NEG
( O
RT O
) O
via O
DNA O
chain O
termination O
after O
incorporation O
of O
the O
nucleotide O
analogue O
. O

Efavirenz O
inhibits O
the O
activity B-DNP
of I-DNP
viral I-DNP
RNA-directed I-DNP
DNA I-DNP
polymerase I-DNP
. O

Lamivudine O
is O
a O
synthetic O
nucleoside O
analogue O
and O
this O
nucleoside O
analogue O
is O
incorporated O
into O
viral O
DNA O
by O
HIV B-DNP
reverse I-DNP
transcriptase I-DNP
and O
HBV B-DNP
polymerase I-DNP
, O
resulting O
in O
DNA B-NEU
chain I-NEU
termination I-NEU
. O

-DOCSTART- O

Immune B-NEG
Thrombocytopenic I-NEG
Purpura I-NEG

-DOCSTART- O

To O
clear O
away O
heat B-NEU
and O
toxic B-NEG
materials I-NEG
, O
relieve O
cough B-NEG
and O
eliminate O
phlegm B-NEG
. O

-DOCSTART- O

syphilis B-NEG
; O
strawberry O
sores B-NEG
; O
syphilitic B-NEG
skin I-NEG
disease I-NEG

-DOCSTART- O

Fatigue B-NEG

-DOCSTART- O

prolapse B-NEG
of O
the O
rectum O

-DOCSTART- O

Hypertension B-NEG

-DOCSTART- O

shortness B-NEG
of I-NEG
breath I-NEG

-DOCSTART- O

cataract B-NEG
and O
nebula O

-DOCSTART- O

clear O
heat B-NEU
and O
calm O
the O
fetus O

-DOCSTART- O

Woman O
, O
Bone B-NEU
Health I-NEU
and O
Osteoporosis B-NEG
, O
Bone B-NEU
metabolism I-NEU
/ I-NEU
density I-NEU
, O
Menopausal B-NEG
woman I-NEG

-DOCSTART- O

convulsive B-NEG
seizure I-NEG

-DOCSTART- O

Like O
other O
macrolides O
, O
it O
then O
penetrates O
bacteria O
cell O
wall O
and O
reversibly O
binds O
to O
domain O
V O
of O
the O
23S O
ribosomal O
RNA O
of O
the O
50S O
subunit O
of O
the O
bacterial O
ribosome O
, O
blocking O
translocation O
of O
aminoacyl B-NEU
transfer-RNA I-NEU
and I-NEU
polypeptide I-NEU
synthesis I-NEU
. O

-DOCSTART- O

Woman O
, O
Eldery O
, O
menopausal B-NEG
woman I-NEG
, O
Others O

-DOCSTART- O

To O
nourish O
yin O
and O
clear O
away O
heat B-NEU
, O
relieve O
restlessness B-NEG
and O
tranquilize O
the O
mind B-DNP
, O
regulate O
the O
equilibrium O
of O
the O
human B-DNP
body I-DNP
, O
improve O
health B-DNP
and O
prolong B-POS
life I-POS
. O

-DOCSTART- O

This O
is O
passing B-NEG
urine I-NEG
unconsciously I-NEG
. O

-DOCSTART- O

menstrual B-NEG
abdominal I-NEG
pain I-NEG

-DOCSTART- O

Intelligence B-POS
, O
Mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
Others O

-DOCSTART- O

stop O
bleeding B-NEG
and O
stabilize O
pain B-NEG

-DOCSTART- O

Proteinuria B-NEG

-DOCSTART- O

distension B-NEG
and O
fullness B-NEG

-DOCSTART- O

disperse O
wart B-NEG

-DOCSTART- O

Treament O
of O
looseness B-NEG
of I-NEG
teeth I-NEG
, O
premature B-NEG
greying I-NEG
of I-NEG
hair I-NEG
and I-NEG
beard I-NEG
, O
dizziness B-NEG
, O
tinnitus B-NEG
, O
aching B-NEG
and I-NEG
weakness I-NEG
of I-NEG
the I-NEG
loins I-NEG
and I-NEG
knees I-NEG
, O
spitting B-NEG
of I-NEG
blood I-NEG
, O
epistaxis B-NEG
, O
hematuria B-NEG
and O
diarrhea B-NEG
with O
bloody B-NEG
stools I-NEG
due O
to O
heat B-NEG
in I-NEG
the I-NEG
blood I-NEG
, O
abnormal B-NEG
uterine I-NEG
bleeding I-NEG
, O
traumatic B-NEG
bleeding I-NEG
. O

-DOCSTART- O

Nephrotic B-NEG
Syndrome I-NEG

-DOCSTART- O

relieve O
Clonorchiasis B-NEG
toxin B-NEG

-DOCSTART- O

To O
clear O
heat B-NEG
and O
disinhibit O
damp B-NEU
, O
cool O
blood B-DNP
and O
resolve O
toxin B-NEG
. O

-DOCSTART- O

To O
dispel O
wind B-NEG
and O
eliminate O
damp B-NEU
, O
stanch O
bleeding B-NEG
and O
disperse O
swelling B-NEG
, O
kill O
worms B-NEG
. O

-DOCSTART- O

dyspnea B-NEG
due O
to O
lung-heat O

-DOCSTART- O

( O
1 O
) O
pestilent B-NEG
lesions I-NEG
; O
leprosy B-NEG
( O
2 O
) O
malignant B-NEG
furuncle I-NEG

-DOCSTART- O

This O
is O
a O
syndrome O
with O
numbness B-NEG
and O
a O
pain B-NEG
due O
to O
Wind-Dampness B-NEG
. O

-DOCSTART- O

Warfarin O
inhibits O
vitamin B-DNP
K I-DNP
reductase I-DNP
, O
resulting O
in O
depletion O
of O
the O
reduced O
form O
of O
vitamin B-DNP
K I-DNP
which O
reduces O
the O
thrombogenicity B-NEG
of I-NEG
clots I-NEG
. O

Heparin O
binds O
to O
antithrombin O
III O
to O
form O
a O
heparin-antithrombin O
III O
complex O
. O

The O
complex O
binds O
to O
and O
irreversibly O
inactivates O
thrombin B-DNP
and O
other O
activated O
clotting B-DNP
factors I-DNP
, O
such O
as O
factors O
IX O
, O
X, O
XI O
, O
and O
XII O
, O
thereby O
preventing O
the O
polymerization B-NEU
of I-NEU
fibrinogen I-NEU
to O
fibrin O
and O
the O
subsequent O
formation B-NEU
of I-NEU
clots I-NEU
. O

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Woman O
, O
absorption B-NEU
, O
Digestion B-NEU
, O
motility B-NEU
, O
Others O
, O
General O
woman O

-DOCSTART- O

Rifampin O
acts O
via O
the O
inhibition O
of O
DNA-dependent O
RNA B-DNP
polymerase I-DNP
, O
leading O
to O
a O
suppression O
of O
RNA B-NEU
synthesis I-NEU
and O
cell O
death O
. O

-DOCSTART- O

dispel O
stasis B-NEG

-DOCSTART- O

Hypertrophy B-NEG
, I-NEG
Left I-NEG
Ventricular I-NEG

-DOCSTART- O

Inhibiting O
the O
growth O
of O
various O
kinds O
of O
dermatomyces B-DNP
. O

-DOCSTART- O

dispel O
cold B-NEG
and O
relieve O
pain B-NEG

-DOCSTART- O

1 O
Its O
decoction O
in O
1:3000-1:200 O
concentration B-POS
inhibits O
the O
growth O
of O
influenzae B-NEG
virus I-NEG
and O
Bacillus B-NEG
dysenteriae I-NEG
in O
vitro.2 O
. O
Promoting O
the O
secretion O
of O
gastric B-DNP
juice I-DNP
and O
enhancing O
the O
digestive B-POS
function I-POS
, O
also O
as O
an O
astringent B-NEU
. O

-DOCSTART- O

infraumbilical B-NEG
cold I-NEG
pain I-NEG

-DOCSTART- O

cool O
the O
blood B-NEU
and O
move O
the O
blood B-NEU

-DOCSTART- O

Diagnostic O
yield O
and O
adverse O
effects O
of O
MRI-guided O
free-hand O
brain O
biopsies O
through O
a O
mini-burr O
hole O
in O
dogs O
with O
encephalitis O
. O

-DOCSTART- O

Sleep B-NEG
Disturbance I-NEG

-DOCSTART- O

To O
drain O
the O
pus O
and O
relieve O
swelling B-NEG
( O
external O
use O
for O
various O
kinds O
of O
severe O
skin B-NEG
lesions I-NEG
; O
oral O
use O
of O
Crotonis O
fried O
yellow O
wax O
for O
bone B-NEG
tuberculosis I-NEG
and O
osteomyelitis B-NEG
) O
. O

-DOCSTART- O

Endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Dermatological B-DNP
systems I-DNP
health I-DNP
, O
Overall O
CVD B-NEG
, O
Diet O
related O
cardiovascular B-NEG
disease I-NEG
, O
General O
skin B-DNP
health I-DNP
, O
Others O
, O
Reproductive B-DNP
systems I-DNP
, O
Protective O
immunity B-NEU

-DOCSTART- O

Methdilazine O
binds O
to O
the O
histamine O
H O
1 O
receptor O
. O

-DOCSTART- O

Gallbladder B-NEG
Neoplasms I-NEG

-DOCSTART- O

Gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
Evacuation B-NEU

-DOCSTART- O

reinforce O
marrow B-DNP

-DOCSTART- O

Its O
volatile O
oil O
is O
an O
expectorant O
and O
antiasthmatic. O
. O

-DOCSTART- O

For O
the O
treatment O
of O
Tuberculosis B-NEG
and O
Tuberculosis-related O
mycobacterial B-NEG
infections I-NEG
. O

-DOCSTART- O

invigorate O
the O
spleen B-DNP

-DOCSTART- O

To O
eliminate O
fluid O
and O
relieve O
edema B-NEG
( O
sthenia-syndrome B-NEG
with O
edema B-NEG
and O
ascites B-DNP
) O
. O

-DOCSTART- O

swelling B-NEG
and O
bearing-down O
pain B-NEG
of O
unilateral O
testis B-DNP
; O
unilateral O
swelling B-NEG
of O
the O
testis B-DNP

-DOCSTART- O

1 O
L-tetrahydropalmatine O
20-40mg/kg O
intraperitoneally O
in O
mice O
and O
15mg/kg O
intravenously O
in O
rabbits O
exert O
analgesic O
and O
sedative B-POS
effects I-POS
. O
2 O
Reducing O
the O
body B-NEG
temperature I-NEG
in O
healthy O
or O
thyroidectomized O
rats O
. O

-DOCSTART- O

( O
1 O
) O
hemorrhoids B-NEG
( O
2 O
) O
polyp B-NEG

-DOCSTART- O

regenerate O
blood B-NEU

-DOCSTART- O

painful O
urinary B-NEG
dysfunction I-NEG
; O
stranguria B-NEG
a O
syndrome O
characterized O
by O
frequent O
, O
painful O
and O
dripping O
urination B-DNP
. O

-DOCSTART- O

wind-heat O
; O
wind O
and O
heat O
; O
wind-heat O
pathogene O
wind O
and O
heat O
blended O
as O
a O
pathogenic O
factor O
. O

-DOCSTART- O

Eye B-NEG
pain I-NEG
, O
eye B-NEG
swelling I-NEG
, O
red B-NEG
eyes I-NEG
and O
tearing B-NEU
. O

-DOCSTART- O

cough B-NEG
due O
to O
phlegm-damp B-NEG

-DOCSTART- O

nausea B-NEG
without O
vomiting B-NEG
. O

-DOCSTART- O

Treatment O
of O
stagnancy B-NEG
of I-NEG
undigested I-NEG
food I-NEG
with O
abdominal B-NEG
distension I-NEG
and O
constipation B-NEG
, O
weakness B-NEG
and O
edema B-NEG
of O
the O
legs O
with O
oliguria B-NEG
. O

-DOCSTART- O

disperse O
goiter B-NEG
core O

-DOCSTART- O

Thoracic O
Surgery O

-DOCSTART- O

acute B-NEG
appendicitis I-NEG
; O
periappendicular B-NEG
abscess I-NEG
; O
intestinal B-NEG
carbuncle I-NEG
; O
intestinal B-NEG
abscess I-NEG

-DOCSTART- O

Small O
dosage O
of O
berberine O
enhances O
the O
action O
of O
acetylcholine O
on O
animals' O
hearts B-DNP
in O
vitro O
, O
while O
large O
dosage O
counteracts O
it O
. O

-DOCSTART- O

Treatment O
of O
menstrual B-NEG
disorders I-NEG
, O
anemia B-NEG
, O
numbness B-NEG
and O
paralysis B-NEG
, O
rheumatic B-NEG
arthralgia I-NEG
. O

-DOCSTART- O

Investigated O
for O
use O
/ O
treatment O
in O
bladder B-NEG
cancer I-NEG
. O

-DOCSTART- O

swelling B-NEG
of O
the O
cheek O
; O
parotitis B-NEG

-DOCSTART- O

Chlorothiazide O
is O
indicated O
as O
adjunctive O
therapy O
in O
edema B-NEG
associated O
with O
congestive B-NEG
heart I-NEG
failure I-NEG
, O
hepatic B-NEG
cirrhosis I-NEG
, O
and O
corticosteroid O
and O
estrogen O
therapy O
. O

It O
is O
also O
indicated O
in O
the O
management O
of O
hypertension B-NEG
either O
as O
the O
sole O
therapeutic O
agent O
or O
to O
enhance O
the O
effectiveness O
of O
other O
antihypertensive O
drugs O
in O
the O
more O
severe O
forms O
of O
hypertension B-NEG
. O

-DOCSTART- O

Hepatitis B-NEG
C I-NEG
, I-NEG
Chronic I-NEG

-DOCSTART- O

1 O
Applicable O
to O
cases O
of O
diarrhea B-NEG
in O
summer O
time O
, O
manifested O
as O
watery B-NEG
diarrhea I-NEG
, O
abdominal B-NEG
fullness I-NEG
, O
increased O
borborygmus B-NEG
, O
nausea B-NEG
, O
feeling O
of O
oppression B-NEG
over O
the O
chest O
, O
fatigue B-NEG
, O
white B-NEG
and I-NEG
smooth I-NEG
fur I-NEG
on I-NEG
the I-NEG
tongue I-NEG
, O
soft O
and O
floating O
, O
slow B-NEG
pulse I-NEG
, O
which O
are O
attribut O

-DOCSTART- O

cool O
the O
blood B-DNP

-DOCSTART- O

Treament O
of O
abdomen B-NEG
pain I-NEG
due O
to O
intestinal B-NEG
worms I-NEG
, O
sores B-NEG
, O
uterine B-NEG
bleeding I-NEG
( O
drug O
carbonizing O
) O
. O

-DOCSTART- O

an O
illness O
in O
which O
phlegm B-NEG
formed O
on O
chest O

-DOCSTART- O

1 O
Containing O
potassium O
acetate O
and O
chloride O
which O
exert O
diuretic O
effect O
. O
2 O
. O
Orall O
adminstration O
of O
its O
decoction O
or O
infusion O
( O
2g/kg O
) O
can O
reduce O
vaccine-induced O
fever B-NEG
in O
rabbits O
. O
3 O
. O
Cardiotonic O
on O
the O
heart O
of O
frog O
weakened O
by O
quinine O
. O
Also O
causing O
constriction B-NEU
of I-NEU
blood I-NEU
vessels I-NEU
and O
rising B-NEU
of I-NEU
blood I-NEU
pressure I-NEU
. O

-DOCSTART- O

Wind-damp B-NEG
impediment I-NEG
pain I-NEG
, O
pain B-NEG
from O
arthritis B-NEG
, O
painful B-NEG
swelling I-NEG
from O
knocks B-NEG
and O
falls B-NEG
, O
amenorrhea B-NEG
, O
dysmenorrhea B-NEG
, O
swollen B-NEG
welling I-NEG
abscess I-NEG
, O
erysipelas B-NEG
, O
goose-foot B-NEG
wind I-NEG
, O
snake B-NEG
or I-NEG
insect I-NEG
bites I-NEG
. O

-DOCSTART- O

Cardiovascular B-NEG
Disorder I-NEG

-DOCSTART- O

Erlotinib O
inhibits O
the O
intracellular O
phosphorylation O
of O
tyrosine O
kinase O
associated O
with O
the O
epidermal O
growth O
factor O
receptor O
( O
EGFR O
) O
which O
is O
expressed O
on O
the O
cell O
surface O
of O
normal O
cells O
and O
cancer B-NEG
cells O
. O

-DOCSTART- O

nocturnal B-NEG
emission I-NEG
; O
emission O
; O
spermatorrhea B-NEG
; O
seminal O
emission O

-DOCSTART- O

disperse O
glomus B-NEG

-DOCSTART- O

Rescinnamine O
Binds O
to O
and O
inhibits O
the O
angiotensin B-DNP
converting I-DNP
enzyme I-DNP
. O
Rescinnamine O
competes O
with O
angiotensin O
I O
for O
binding O
at O
the O
angiotensin-converting B-DNP
enzyme I-DNP
, O
blocking O
the O
conversion O
of O
angiotensin B-DNP
I I-DNP
to O
angiotensin B-DNP
II I-DNP
. O
Inhibition O
of O
ACE O
results O
in O
decreased O
plasma B-DNP
angiotensin I-DNP
II I-DNP
. O
As O
angiotensin B-DNP
II I-DNP
is I-DNP
a O
vasoconstrictor B-NEG
and O
a O
negative-feedback O
mediator O
for O
renin B-DNP
activity O
, O
lower O
concentrations O
result O
in O
a O
decrease O
in O
blood B-NEU
pressure I-NEU
and O
stimulation O
of O
baroreceptor O
reflex O
mechanisms O
, O
which O
leads O
to O
decreased O
vasopressor B-NEU
activity O
and O
to O
decreased O
aldosterone B-DNP
secretion O
. O

-DOCSTART- O

Bradycardia B-NEG
, O
sick B-NEG
sinus I-NEG
syndrome I-NEG
, O
angina B-NEG
and O
cardiac B-NEG
insufficiency I-NEG
, O
arrhythmia B-NEG
. O

-DOCSTART- O

insufficiency O
of O
heart B-DNP
Gi O

-DOCSTART- O

To O
reinforce O
qi O
and O
invigorate O
the O
function O
of O
the O
spleen B-DNP
and O
the O
lung B-DNP
. O

-DOCSTART- O

Eldery O
, O
Others O

-DOCSTART- O

Treatment O
of O
carbuncle B-NEG
and O
boil B-NEG
at O
the O
early O
stage O
or O
formation B-NEG
of I-NEG
abscess I-NEG
difficult O
to O
burst B-NEU
, O
external O
use O
for O
scabies B-NEG
and O
leprosy B-NEG
. O

-DOCSTART- O

clear O
the O
lung B-DNP
and O
discharge O
fire O

-DOCSTART- O

consumption B-NEG
; O

deficiency B-NEG
syndrome I-NEG
; O

disease B-NEG
due O
to O
asthenia B-NEG
of O
the O
viscera O

-DOCSTART- O

Used O
to O
prolong O
the O
time O
to O
recurrence O
of O
paroxysmal B-NEG
atrial I-NEG
fibrillation/flutter I-NEG
( O
PAF B-NEG
) O
associated O
with O
disabling O
symptoms O
in O
patients O
without O
structural B-NEG
heart I-NEG
disease I-NEG
. O
Also O
used O
for O
the O
treatment O
of O
life-threatening O
documented O
ventricular B-NEG
arrhythmias I-NEG
, O
such O
as O
sustained B-NEG
ventricular I-NEG
tachycardia I-NEG
. O

-DOCSTART- O

[Case O
of O
pneumonitis B-NEG
caused O
by O
Yokukansan] O
. O

-DOCSTART- O

sore B-NEG
throat I-NEG
; O

swollen B-NEG
and O
pailful B-NEG
throat I-NEG

-DOCSTART- O

restore O
depression B-NEG
and O
dissipate O
bind O

-DOCSTART- O

Woman O
, O
Mood O
, O
Menopausal B-DNP
woman I-DNP
, O
Dermatological B-DNP
systems I-DNP
health O
, O
General O
woman O
, O
General O
skin B-DNP
health I-DNP
, O
Others O
, O
Mental B-DNP
state I-DNP
and O
performance O

-DOCSTART- O

difficulty B-NEG
in I-NEG
feces I-NEG
and O
urine B-DNP

-DOCSTART- O

Wind-cold B-NEG
common O
cold B-NEG
, O
summerheat O
damage O
, O
vomiting B-NEG
diarrhea B-NEG
with O
abdominal O
pain B-NEG
, O
dribbling O
pain B-NEG
of O
urination O
, O
wind-damp B-NEG
impediment O
pain B-NEG
, O
cough B-NEG
and O
asthma B-NEG
, O
bronchial O
asthma B-NEG
. O

-DOCSTART- O

invigorate O
the O
spleen B-DNP
and O
disperse O
food O

-DOCSTART- O

RK-0202 O
, O
an O
oral O
rinse O
for O
the O
prevention O
and O
treatment O
of O
mucositis B-NEG
, O
is O
based O
on O
the O
company's O
ProGelz O
technology O
and O
is O
comprised O
of O
the O
potent O
antioxidant O
N-acetylcysteine O
in O
a O
polymer O
matrix O
. O

-DOCSTART- O

Investigated O
for O
use O
/ O
treatment O
in O
breast B-NEG
cancer I-NEG
, O
head B-NEG
and I-NEG
neck I-NEG
cancer I-NEG
, O
and O
lung B-NEG
cancer I-NEG
. O

-DOCSTART- O

Prostate B-NEG
cancer I-NEG

-DOCSTART- O

Dental B-NEG
Plaque I-NEG

-DOCSTART- O

For O
the O
treatment O
of O
gastroesophageal B-NEG
reflux I-NEG
disease I-NEG
( O
GERD B-NEG
) O
. O

It O
is O
also O
used O
in O
treating O
nausea B-NEG
and O
vomiting B-NEG
, O
and O
to O
increase O
gastric B-NEU
emptying I-NEU
. O

Occasionally O
used O
in O
Cushing's B-NEG
syndrome I-NEG
. O

-DOCSTART- O

cold O
dysentery B-NEG

-DOCSTART- O

1 O
Broad-spectrum O
antibacteric O
. O
Its O
antibacterial O
components O
are O
para-hydroxyphenylacetic O
acid O
, O
salicylic O
acid O
, O
vanillic O
acid O
, O
pyromucic O
acid O
and O
hydroquinone O
. O
2 O
. O
Its O
1/1800-1/1600 O
decoction O
inhibits O
the O
growth B-NEU
of I-NEU
leptospira I-NEU
. O
3 O
. O
Anti-trichomonas B-POS
vaginalis I-POS
in O
vitro O
. O
4 O
. O
Its O
component O
, O
senecionine O
, O
is O
anticarcinogenic O
on O
Walker O
sarcoma256 O
. O

-DOCSTART- O

Decompensated B-NEG
Cirrhosis I-NEG

-DOCSTART- O

Reducing O
signs O
and O
symptoms O
of O
Crohn's B-NEG
disease I-NEG
and O
treatment O
of O
moderately O
to O
severely O
active O
rheumatoid B-NEG
arthritis I-NEG
( O
RA B-NEG
) O
. O

-DOCSTART- O

For O
eliminating O
toxic B-NEG
materials I-NEG
, O
dissolving O
rottenness B-NEG
and O
growing O
new O
muscles B-NEG

-DOCSTART- O

1 O
Aloperine O
inhibits O
exudative B-NEG
inflammation I-NEG
and O
hemolysis B-NEG
of O
red O
blood O
cells O
2 O
. O
Its O
decoction O
or O
sophocarpine O
relieves O
asthma B-NEG
in O
guinea-pigs O
induced O
by O
acetylcholine O
and O
histamine O
. O
3 O
. O
Sophocarpine O
or O
matrine O
inhibits O
sarcoma180 O
in O
vitro O
. O

-DOCSTART- O

a O
disease O
like O
a O
cholera B-NEG
. O
That O
Has O
a O
abdominal O
pain B-NEG
, O
vomiting B-NEG
and O
diarrhea B-NEG
caused O
by O
dirty O
and O
acute O
filthy O
Gi O

-DOCSTART- O

Endocrine B-DNP
system I-DNP
, O
insulin B-DNP
sensitivity I-DNP
and O
diabetes B-NEG
risk O
, O
Body O
weight O
regulation O
, O
Improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
Endocrine O
& O
reproductive B-DNP
systems I-DNP

-DOCSTART- O

1 O
For O
cases O
of O
menorrhagia B-NEG
accompanied O
with O
listlessness B-NEG
and O
pale B-NEG
complexion I-NEG
due O
to O
deficiency B-NEG
of I-NEG
vital I-NEG
energy I-NEG
Radix O
Ginseng O
Jilin O
to O
invigorate O
vital B-POS
energy I-POS
and O
control O
blood B-DNP
of O
profuse B-NEG
uterine I-NEG
bleeding I-NEG
leading O
to O
deadly O
coldness B-NEG
of I-NEG
limbs I-NEG
and O

-DOCSTART- O

Heat B-NEU
bind O
and O
accumulation O
, O
constipation O
w O
ith O
abdominal B-NEG
pain I-NEG
, O
edema B-NEG
distention I-NEG
fullness I-NEG
. O

-DOCSTART- O

Treament O
of O
arthritis B-NEG
with O
ankylosis B-NEG
, O
aching B-NEG
and I-NEG
heaviness I-NEG
sensation I-NEG
of O
the O
loins O
and O
knees O
, O
systremma B-NEG
due O
to O
vomiting B-NEG
and O
diarrhea B-NEG
, O
edema B-NEG
and O
weakness B-NEG
of I-NEG
the I-NEG
legs I-NEG
. O

-DOCSTART- O

Rapamycin O
binds O
to O
the O
immunophilin O
FK O
Binding O
Protein-12 O
( O
FKBP-12 O
) O
to O
generate O
an O
immunosuppressive B-DNP
complex I-DNP
that O
binds O
to O
and O
inhibits O
the O
activation O
of O
the O
mammalian O
Target O
Of O
Rapamycin O
( O
mTOR O
) O
, O
a O
key O
regulatory O
kinase O
. O

This O
results O
in O
inhibition O
of O
T B-DNP
lymphocyte I-DNP
activation I-DNP
and I-DNP
proliferation I-DNP
that O
occurs O
in O
response O
to O
antigenic O
and O
cytokine O
( O
IL-2 O
, O
IL-4 O
, O
and O
IL-15 O
) O
stimulation O
and O
inhibition O
of O
antibody B-DNP
production I-DNP
. O

Imatinib O
binds O
to O
an O
intracellular O
pocket O
located O
within O
tyrosine O
kinases O
( O
TK O
) O
, O
thereby O
inhibiting O
ATP B-NEU
binding I-NEU
and O
preventing O
phosphorylation B-NEU
and O
the O
subsequent O
activation B-NEU
of I-NEU
growth I-NEU
receptors I-NEU
and O
their O
downstream O
signal B-DNP
transduction I-DNP
pathways I-DNP
. O

This O
agent O
inhibits O
TK B-DNP
encoded O
by O
the O
bcr-abl O
oncogene O
as O
well O
as O
receptor B-DNP
TKs I-DNP
encoded O
by O
the O
c-kit O
and O
platelet-derived B-DNP
growth I-DNP
factor I-DNP
receptor I-DNP
( O
PDGFR O
) O
oncogenes O
. O

Biochemical O
analyses O
raise O
the O
possibility O
that O
inhibition O
of O
4I-BP1 O
phosphorylation B-NEU
may O
be O
particularly O
important O
for O
the O
synergistic O
effects O
of O
PTK O
inhibitor O
/ O
rapamycin O
combinations O
. O

-DOCSTART- O

To O
dissipate O
stasis B-NEG
and O
quicken O
blood B-DNP
, O
relieve O
pain B-NEG
. O

-DOCSTART- O

To O
remove O
heat B-NEG
, O
to O
promote O
the O
production O
of O
body B-NEU
fluid I-NEU
, O
and O
to O
facilitate O
the O
drainage O
of O
pus B-NEG
and O
the O
subsidence O
of O
swelling B-NEG
. O

-DOCSTART- O

carbuncle B-NEG
and O
cellulitis B-NEG
of O
the O
back O
; O
carbuncle B-NEG
on O
the O
back O

-DOCSTART- O

thirst B-NEU

-DOCSTART- O

shortness B-NEG
of I-NEG
breath I-NEG
short B-NEG
, I-NEG
rapid I-NEG
and I-NEG
interrupted I-NEG
breathing I-NEG
. O

-DOCSTART- O

Treatment O
of O
fever B-NEG
with O
constipation B-NEG
, O
retention O
of O
the O
feces O
and O
abdominal B-NEG
pain I-NEG
, O
dysentery B-NEG
with O
inadequate O
discharge O
from O
the O
bowels B-DNP
, O
jaundice B-NEG
caused O
by O
damp-heat B-NEG
, O
haematemesis B-NEG
, O
epistaxis B-NEG
, O
inflammation B-NEG
of O
eye O
and O
swelling B-NEG
of O
the O
throat O
due O
to O
heat B-NEU
in O
the O
blood O
, O
appendicitis B-NEG
with O
abdominal B-NEG
pain I-NEG
, O
boils B-NEG
, O
sores B-NEG
and O
abscess B-NEG
, O
amenorrhea B-NEG
due O
to O
blood B-NEG
stasis I-NEG
, O
traumatic B-NEG
injuries I-NEG
, O
hemorrhage B-NEG
from O
the O
upper B-DNP
gastrointestinal I-DNP
tract I-DNP
. O
External O
use O
for O
scalds B-NEG
and O
burns.Radixet O
Rhizoma O
Rhei O
( O
stir-fried O
with O
wine O
) O
Inflammation B-NEG
of O
the O
eye O
, O
swelling B-NEG
of O
the O
throat O
and O
painful O
swelling B-NEG
of O
the O
gums O
. O
Radix O
et O
Rhizoma O
Rhei O
( O
prepared O
) O
Boils B-NEG
, O
sores B-NEG
and O
abscess B-NEG
. O
Radix O
et O
Rhizoma O
Rhei O
( O
carbonized O
) O
Hemorrhage B-NEG
with O
blood B-NEG
stasis I-NEG
due O
to O
heat B-NEU
in O
the O
blood O
. O

-DOCSTART- O

Bipolar B-NEG
Disorder I-NEG

-DOCSTART- O

sores B-NEG
with O
swelling B-NEG

-DOCSTART- O

1 O
nocturnal B-NEG
enuresis I-NEG
; O
bed-wetting B-NEG
2 O
incontinence B-NEG
of I-NEG
urine I-NEG

-DOCSTART- O

To O
strengthen O
the O
spleen B-DNP
. O

-DOCSTART- O

To O
invigo O
rate O
the O
function B-NEU
of I-NEU
the I-NEU
spleen I-NEU
, O
to O
regulate O
the O
function B-NEU
of I-NEU
the I-NEU
stomach I-NEU
, O
and O
to O
promote O
the O
flow B-NEU
of I-NEU
milk I-NEU
. O

-DOCSTART- O

The O
primary O
activity O
of O
insulin O
is O
the O
regulation O
of O
glucose B-NEU
metabolism I-NEU
. O

Insulin O
promotes O
glucose O
and O
amino O
acid O
uptake O
into O
muscle O
and O
adipose O
tissues O
, O
and O
other O
tissues O
except O
brain O
and O
liver O
. O

It O
also O
has O
an O
anabolic O
role O
in O
stimulating O
glycogen B-NEU
, I-NEU
fatty I-NEU
acid I-NEU
, I-NEU
and I-NEU
protein I-NEU
synthesis I-NEU
. O

Insulin O
inhibits O
gluconeogenesis B-DNP
in O
the O
liver O
. O

Insulin O
binds O
to O
the O
insulin O
receptor O
( O
IR O
) O
, O
a O
heterotetrameric O
protein O
consisting O
of O
two O
extracellular O
alpha O
units O
and O
two O
transmembrane O
beta O
units O
. O

The O
binding O
of O
insulin O
to O
the O
alpha O
subunit O
of O
IR O
stimulates O
the O
tyrosine B-DNP
kinase I-DNP
activity I-DNP
intrinsic I-DNP
to O
the O
beta O
subunit O
of O
the O
receptor O
. O

The O
bound O
receptor O
is O
able O
to O
autophosphorylate O
and O
phosphorylate O
numerous O
intracellular O
substrates O
such O
as O
insulin O
receptor O
substrates O
( O
IRS O
) O
proteins O
, O
Cbl O
, O
APS O
, O
Shc O
and O
Gab O

These O
activated O
proteins O
, O
in O
turn O
, O
lead O
to O
the O
activation B-DNP
of I-DNP
downstream I-DNP
signaling I-DNP
molecules I-DNP
including O
PI3 O
kinase O
and O
Akt O
. O

Akt O
regulates O
the O
activity B-DNP
of I-DNP
glucose I-DNP
transporter I-DNP
4 I-DNP
( O
GLUT4 O
) O
and O
protein O
kinase O
C O
( O
PKC O
) O
which O
play O
a O
critical O
role O
in O
metabolism O
and O
catabolism O
. O

-DOCSTART- O

clear O
the O
head B-DNP
and O
eyes B-DNP

-DOCSTART- O

Pulmonary B-NEG
Disease I-NEG
, O
Chronic B-NEG
Obstructive I-NEG

-DOCSTART- O

Heavy O
flow O
in O
period O
due O
to O
blood B-NEG
stagnation I-NEG

-DOCSTART- O

Investigated O
for O
use/treatment O
in O
fibromyalgia B-NEG
. O

-DOCSTART- O

Investigated O
for O
use O
/ O
treatment O
in O
benign B-NEG
prostatic I-NEG
hyperplasia I-NEG
. O

-DOCSTART- O

Dalfopristin O
inhibits O
the O
early O
phase B-NEU
of I-NEU
protein I-NEU
synthesis I-NEU
by O
acting O
on O
bacterial O
ribosome O
. O
Quinupristin O
binds O
to O
a O
nearby O
site O
on O
the O
50S O
ribosomal O
subunit O
and O
prevents O
elongation B-NEU
of I-NEU
the I-NEU
polypeptide I-NEU
as O
well O
as O
causing O
incomplete O
chains O
to O
be O
released O
. O

-DOCSTART- O

Amenorrhea B-NEG
, O
menstrual B-NEG
disorders I-NEG
, O
difficult O
labour O
, O
retention B-NEG
of I-NEG
placenta I-NEG
, O
postpartum B-NEG
abdominal I-NEG
pain I-NEG
due O
to O
blood B-NEG
stasis I-NEG
. O

-DOCSTART- O

Cough B-NEG
in O
phthisis B-NEG
, O
dyspnea B-NEG
in O
the O
aged O
, O
depressed B-NEG
sensation I-NEG
and O
stuffiness B-NEG
in O
the O
chest O
. O

-DOCSTART- O

cooling O
throat B-DNP

-DOCSTART- O

frequent O
urination B-DNP

-DOCSTART- O

clear O
heat B-NEU
and O
dry O
dampness B-NEU

-DOCSTART- O

This O
disease O
has O
a O
characteristics O
of O
gradual O
onset O
, O
plat O
form O
of O
ulceration B-NEG
, O
mild O
or O
no O
pain B-NEG
, O
no O
change O
of O
skin O
color O
or O
dark O
reddish O
or O
blackened O
color O
change O
, O
mild O
or O
no O
fever B-NEG
, O
not O
well O
subsided O
or O
healed O
, O
occasional O
lump B-NEG
formation I-NEG
, O
no O
pus B-NEG
, O
long O
duration O
of O
treatment O
, O
thin O
colourful O
discharge O
, O
Chimse O
and O
weak O
Mac O
. O

-DOCSTART- O

Phlegm B-NEG
stagnation I-NEG
in O
chest O
and O
diaphragm O
, O
glomus O
in O
chest O
, O
distention O
in O
rib-side O
, O
food O
accumulation O
, O
retching O
counterflow O
. O

-DOCSTART- O

reddish B-NEG
turbid I-NEG
urine I-NEG

-DOCSTART- O

spasmodic B-NEG
contraction I-NEG
of O
tendons O
and O
meridian O

-DOCSTART- O

Dragon's O
blood B-DNP
( O
Xuejie O
) O
is O
used O
with O
Frankincense O
( O
Ruxiang O
) O
and O
Myrrh O
( O
Moyao O
) O
in O
the O
formula O
Qili O
San O
. O

-DOCSTART- O

For O
prophylaxis O
of O
respiratory B-NEG
diseases I-NEG
casued O
by O
respiratory B-NEG
syncytial I-NEG
virus I-NEG
. O

-DOCSTART- O

heat B-NEG
in O
the O
stomach O
; O

stomach B-NEG
heat I-NEG
; O

stomach B-DNP
affected O
by O
heat B-NEG
impairment I-NEG
of O
the O
stomach O
by O
pathogenic B-NEG
heat I-NEG
or O
taking O
excessive O
heat-producing O
food O
, O
marked O
by O
thirst B-NEU
, O
halitosis B-NEG
, O
hyperorexia B-NEG
, O
oliguria B-NEG
with O
dark B-NEG
urine I-NEG
, O
constipation B-NEG
or O
even O
ulceration B-NEG
of O
the O
mouth O
, O
gingivitis B-NEG
. O

-DOCSTART- O

For O
the O
treatment O
of O
documented O
ventricular B-NEG
arrhythmias I-NEG
, O
such O
as O
sustained B-NEG
ventricular I-NEG
tachycardia I-NEG
, O
that O
, O
in O
the O
judgment O
of O
the O
physician O
, O
are O
life-threatening O
. O

-DOCSTART- O

chronic O
cough O
due B-NEG
to O
deficiency B-NEG
of O
the O
lung O

-DOCSTART- O

constipation B-NEG
and O
difficulty B-NEG
in I-NEG
urination I-NEG

-DOCSTART- O

Treament O
of O
heat B-NEU
in I-NEU
the I-NEU
lung I-NEU
with O
cough B-NEG
, O
sticky B-NEG
and I-NEG
bloody I-NEG
sputum I-NEG
, O
and O
distress B-NEG
in I-NEG
the I-NEG
chest I-NEG
. O

-DOCSTART- O

fullness B-NEU
of O
chest O
and O
abdomen O
. O
Indigestion B-NEG
caused O
by O
that O
cold O
pathogen O
of O
the O
middle-Cho O
disturb O
function O
of O
stomach B-DNP
and O
spleen B-DNP
. O
Feel O
tiring B-NEG
and O
heavy O
, O
pain B-NEG
in O
joint O
due O
to O
damp O
pathogen O

-DOCSTART- O

It O
causes O
blood B-DNP
vessels I-DNP
to O
narrow O
, O
resulting O
in O
an O
increase O
in O
blood B-NEU
pressure I-NEU
. O

-DOCSTART- O

Pulmonary O
Aspiration O

-DOCSTART- O

settle O
fright O

-DOCSTART- O

Tardive B-NEG
Dyskinesia I-NEG
. O

-DOCSTART- O

Human B-NEG
Immunodeficiency I-NEG
Virus I-NEG
Infection I-NEG

-DOCSTART- O

major O
red O
and O
white O
dysentery B-NEG

-DOCSTART- O

Its O
biochemical O
mechanism O
of O
action O
is O
unknown O
, O
although O
data O
are O
available O
to O
suggest O
that O
the O
drug O
modifies O
the O
peripheral O
metabolism O
of O
steroids O
as O
well O
as O
directly O
suppressing O
the O
adrenal B-DNP
cortex I-DNP
. O

-DOCSTART- O

To O
dispel O
wind B-NEG
and O
eliminate O
damp B-NEU
, O
quicken O
blood B-DNP
and O
resolve O
toxin B-NEG
. O

-DOCSTART- O

To O
dispel O
wind B-NEG
and O
eliminate O
damp B-NEG
, O
move O
qi O
and O
quicken O
blood B-DNP
. O

-DOCSTART- O

dyspnea B-NEG
and O
tachypnea B-NEG
; O

shortness B-NEG
of I-NEG
breath I-NEG

-DOCSTART- O

fever B-NEG
with O
affection O
by O
cold B-NEG

-DOCSTART- O

Keishibukuryogan O
, O
one O
of O
the O
traditional O
herbal O
formulations O
, O
is O
used O
clinically O
to O
improve O
blood B-NEU
circulation I-NEU
. O

In O
this O
study O
, O
we O
examined O
the O
effects O
of O
keishibukuryogan O
on O
glucose B-NEU
and I-NEU
lipids I-NEU
metabolism I-NEU
in O
Otsuka O
Long-Evans O
Tokushima O
Fatty O
( O
OLETF O
) O
rats O
, O
an O
animal O
model O
of O
type O
2 O
diabetes O
. O

Forty-five-week-old O
male O
OLETF O
rats O
were O
divided O
into O
three O
groups O
: O
diabetic O
control O
rats O
given O
a O
standard O
chow O
; O
diabetic O
rats O
given O
keishibukuryogan O
( O
0.03 O
, O
w/w O
in O
chow O
) O
; O
diabetic O
rats O
given O
pioglitazone O
( O
0.0001 O
, O
w/w O
in O
chow O
) O
. O

Oral O
administration O
of O
keishibukuryogan O
produced O
significant O
improvement O
against O
impaired O
glucose O
tolerance O
. O

On O
the O
other O
hand O
, O
fasting O
serum B-NEU
glucose I-NEU
and I-NEU
insulin I-NEU
levels I-NEU
, O
and O
the O
homeostasis O
index O
of O
insulin O
resistance O
did O
not O
change O
by O
keishibukuryogan O
treatment O
. O

Against O
lipid O
parameters O
, O
keishibukuryogan O
significantly O
lowered O
serum O
total O
cholesterol B-NEU
and I-NEU
triglyceride I-NEU
levels I-NEU
, O
and O
the O
hepatic O
total O
cholesterol B-NEU
level I-NEU
. O

Keishibukuryogan O
treatment O
also O
significantly O
reduced O
the O
serum O
leptin B-NEU
level I-NEU
, O
but O
it O
had O
no O
effect O
on O
the O
serum O
adiponectin B-NEU
level I-NEU
. O

Additionally O
, O
keishibukuryogan O
showed O
significant O
effects O
on O
epididymal O
adipose B-NEU
tissue I-NEU
by O
decreasing O
the O
size O
of O
fat B-DNP
cells I-DNP
and O
on O
skeletal O
muscle O
by O
reducing O
TNF-alpha B-DNP
protein O
content O
. O

From O
these O
results O
, O
it O
was O
suggested O
that O
keishibukuryogan O
exerts O
beneficial O
effects O
on O
the O
features O
associated O
with O
type B-NEG
2 I-NEG
diabetes I-NEG
. O

-DOCSTART- O

eliminate O
melasma B-NEG

-DOCSTART- O

pain B-NEG
and O
swelling B-NEG
of O
testis O

-DOCSTART- O

food B-NEG
damage I-NEG
; O

injury B-NEG
due O
to O
improper O
diet O
; O

eating O
food O
much O
injury B-NEG
of O
spleen O
and O
stomach O

-DOCSTART- O

forceful O
pulse O

-DOCSTART- O

Treatment O
of O
endemic B-NEG
goiter I-NEG
, O
hyperthyroidism B-NEG
, O
whooping B-NEG
cough I-NEG
, O
cough B-NEG
of O
lung-heat O
type O
, O
thyroid B-NEG
adenoma I-NEG
, O
thyroid B-NEG
cancer I-NEG
, O
tumour B-NEG
of O
digestive O
tract O
, O
lung B-NEG
and I-NEG
mammary I-NEG
cancer I-NEG
, O
etc O
. O

-DOCSTART- O

stomachache B-NEG

-DOCSTART- O

Uncaria O
Hook O
( O
UH O
) O
alkaloids O
are O
involved O
in O
the O
beneficial O
effects O
of O
Yokukansan O
. O

However O
, O
the O
pharmacokinetics O
of O
UH O
alkaloids O
after O
oral O
administration O
of O
Yokukansan O
has O
not O
yet O
been O
sufficiently O
investigated O
. O

Therefore O
, O
we O
developed O
and O
validated O
a O
sensitive O
and O
specific O
high-performance O
liquid O
chromatography O
with O
tandem O
mass O
spectrometry O
( O
LC/MS/MS O
) O
method O
for O
the O
simultaneous O
quantitation O
of O
seven O
UH O
alkaloids O
( O
corynoxeine O
, O
isocorynoxeine O
, O
rhynchophylline O
, O
isorhynchophylline O
, O
hirsutine O
, O
hirsuteine O
and O
geissoschizine O
methyl O
ether O
) O
in O
rat O
plasma O
and O
brain O
. O

After O
protein O
precipitation O
with O
acetonitrile O
, O
chromatographic O
separation O
was O
performed O
using O
an O
Ascentis O
Express O
RP-amide O
column O
, O
with O
gradient O
elution O
with O
0.002 O
formic O
acid O
and O
acetonitrile O
at O
0.3 O
mL/min O
. O

All O
analytes O
in O
the O
plasma O
and O
brain O
showed O
good O
linearity O
over O
a O
wide O
concentration O
range O
(r O
> O
0.995 O
) O
. O

Intra-day O
and O
inter-day O
variations O
of O
each O
constituent O
were O
8.6 O
and O
0.08 O
or O
less O
in O
the O
plasma O
, O
and O
14.9 O
and O
0.15 O
or O
less O
in O
the O
brain O
, O
respectively O
. O

The O
validated O
LC/MS/MS O
method O
was O
applied O
in O
the O
pharmacokinetic O
studies O
of O
UH O
alkaloids O
after O
oral O
administration O
of O
Yokukansan O
to O
rats O
. O

In O
the O
plasma O
, O
rhynchophylline O
, O
hirsutine O
, O
hirsuteine O
and O
geissoschizine O
methyl O
ether O
were O
detected O
, O
but O
only O
geissoschizine O
methyl O
ether O
was O
detected O
in O
the O
brain O
. O

These O
results O
suggest O
that O
geissoschizine O
methyl O
ether O
is O
an O
important O
constituent O
of O
the O
pharmacological O
effects O
of O
Yokukansan O
. O

-DOCSTART- O

wind B-NEG
syndrome I-NEG

-DOCSTART- O

acute O
infantile B-NEG
convulsion I-NEG

-DOCSTART- O

alleviate O
edema B-NEG
and O
toxin B-NEG

-DOCSTART- O

Hepatitis B-NEG
B I-NEG
Reactivation I-NEG

-DOCSTART- O

